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Abstract
Hydrogen deuterium exchange (HDX) coupled with mass spectrometry is widely used for
probing protein structure and dynamics. Protein-ligand interactions usually induce a
reduction in the measured HDX rates an effect that may be ascribed to stabilization of the
protein structure. This work aims to improve the general understanding of the changes in
HDX patterns associated with ligand binding.
We initially applied HDX for studying differences between oxy-hemoglobin (OxyHb) and aquomet-hemoglobin (Chapter 2). The results show that the α and β subunits
respond differently to the oxy to aquomet transition with the heme binding pocket being
destabilized in both cases. The results suggest that enhanced structural dynamics in the heme
binding pocket may have adverse effects on heme-protein interactions.
Chapter 3 focuses on the different scenarios that can be encountered in an HDX
experiment upon ligand binding. Myoglobin and hemoglobin were used as model systems,
focusing on the oxy and deoxy states of both proteins. Our results demonstrate that ligand
binding can be stabilizing or destabilizing, leading to decreased or increased HDX rates
respectively.
In Chapters 4 HDX was used to probe the changes in structural dynamics of
caseinolytic protease P (ClpP), an antibiotic drug target, after binding ADEP antibiotics. The
mechanism of ADEP binding and the N-terminal structure of ClpP is not well understood
with conflicting x-ray structures reported in literature. Our findings demonstrate that the Nterminus of ClpP remains quite unstructured after ADEP binding, while belt region
undergoes tightening.

ii

Pin 1, a peptidyl prolyl isomerase, binding to a cyclic peptide inhibitor was studied in
Chapter 5. Characterization of Pin1-CRYPEVEIC interactions by other techniques has been
difficult. This study demonstrates that binding of the inhibitor triggers an overall stabilization
of Pin 1. We identify a loop that interacts with basic sites of the ligand and that becomes
destabilized upon ligand binding. This destabilization is ascribed to steric clashes between
the peptide inhibitor and the protein

Keywords: hydrogen-deuterium exchange, mass spectrometry, hemoglobin, myoglobin,
ClpP, Pin1, ligand binding
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Chapter 1. Introduction
1.1. Protein Structures
Proteins play important roles in virtually all biological processes. While performing their
functions many proteins undergo conformational changes which are essential for enzyme
catalysis, transport, or energy conversion.1 Proteins adopt specific higher order structures via
folding pathways that are still not fully understood.2 Misfolding can lead to diseases such as
Alzheimer’s, Parkinson’s and other disorders.3 Even in the native state, proteins display
considerable flexibility ranging from localized fluctuations to large conformational
transitions. Ligand binding can trigger structural changes that lead to an increase or decrease
in activity.4-5 Ligands that cause such conformational switching include inhibitors, metal ions
and hormones.6 Deciphering protein conformational dynamics, folding pathways and ligandinduced structural changes remain a fundamental research goal.

1.2. Methods for Studying Protein Structure
Numerous methods are available for the study of protein structures. These techniques are
useful for both biochemical and clinical applications.

A brief discussion of the most

common methods is given below.

1

1.3. "Traditional" Methods
1.3.1. X-ray crystallography
X-ray crystallography remains the gold standard for solving the 3D conformation
proteins with atomic resolution. This method is amenable to the study of protein 3D
structures because X-ray wavelengths are comparable to the ~1Å range typically encountered
for chemical bonds. A basic X-ray diffractometer includes a radiation source, and a detector
(Figure 1-1).

X-ray beam
Crystal
Detector
Plate
Figure 1-1: Schematic representation of an X-ray diffractometer

2

Protein X-ray crystallography was first implemented in the 1950s for solving the
structure of hemoglobin and myoglobin.7 The atomic coordinates derived from X-ray
crystallography are usually accompanied by displacement parameters also known as Bfactors. B-factor measures primarily the molecular disorder in the crystal and this is used as
an indirect estimate of the dynamics of the protein. B-factor also measures other errors in
addition to thermal motions in proteins crystal structures.8 It is widely recognized that
proteins are not static structures and they constantly sample different conformational states in
solution.9 The dynamic information on protein crystals are therefore limited because the
proteins are modelled as single conformations.10-11 Although X-ray crystallography is widely
used, crystal growth remains a challenge as not all proteins are amenable to crystallization.
Also, X-ray data provide static pictures, thereby glossing over the intrinsic dynamics of
proteins.

1.3.2. Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectroscopy represents another tool for studying proteins. NMR is a
phenomenon during which nuclei absorb particular radio frequencies in a strong external
magnetic field. Depending on the type of interaction with the electromagnetic radiation
insight can be gleaned into the nuclear identity and environment. For a nucleus to be NMRvisible, it must have a non-zero spin.

Examples include 1H,

13

C,

15

N and

31

P. The

incorporation of deuterium into the protein backbone eliminates some NMR proton signals
because 2H is not an NMR-active nucleus.12-13 NMR spectroscopy is a powerful technique for
probing the structure and dynamics of biopolymers at the atomic level. NMR relaxation
3

measurements of 13C or 15N nuclei allow the study of molecular motions on the picosecond to
microsecond time scales. Heteronuclear NMR can also be used to determine protein
structures in solution.14 The technique, however, suffers size limitation problems.15

1.3.3. Optical Methods
Optical techniques are widely used for probing protein structural features. Examples
include UV-Visible (UV-VIS) absorption spectroscopy, circular dichroism (CD) and
fluorescence spectroscopy. These methods are quite popular because they are easy to use,
sensitive, and proteins can be studied directly under physiological conditions with good
sample recovery after analysis. They represent, however, low resolution tools.
CD spectroscopy is an absorption-based method that measures the difference of left
and right circularly polarized light. A CD spectrum is observable for chiral molecules. This
technique is often used to evaluate secondary structural elements in proteins. Different
structures generate characteristic CD signals. For example, proteins with a high α-helical
content will give CD spectra with a minimum at 222 nm. β-sheet structures have a minimum
around 215 nm, while for random coil structures the minimum appears at ~202 nm.16 Tertiary
structure information can also be obtained when wavelengths between 250-350 nm are
scanned.17
UV-Vis spectroscopy works well when the protein contains a chromophore such as a
conjugated π system. It is most useful for measuring protein concentrations. Also, small
changes protein structure can be reflected in alterations of the absorption maxima. A good
example is the conversion of oxyhemoglobin to deoxyhemoglobin. The change in the ligation
4

state of the heme chromophore is reflected by a shift in the absorption maxima from 415 nm
to 430 nm.18 Absorbance (A) is defined as

  log

1.1

where I0 is the initial light intensity and I is the transmitted intensity.19 The absorbance of a
chromophore is related to its concentration according to Beer Lambert’s law.

 εCd

1.2

where d is the pathlength of the cuvette, C is concentration and ε is the molar absorption
coefficient.
Fluorescence spectroscopy is another optical technique that is routinely used for
protein structural analyses. An electronically excited chromophore can relax to the ground
state via photon emission to generate fluorescence. Tryptophan is the most commonly used
intrinsic fluorophore.20 Fӧrster resonance energy transfer (FRET) is fluorescence technique
that is particularly useful for probing molecular structure. In FRET, the energy transfer from
an excited donor fluorophore to an acceptor depends on the distance between the two
fluorophores. 21 FRET efficiency is defined as
5




   

1.3

Where R is the distance between donor and acceptor and Ro is the Fӧrster radius for E = 0.5.
The sensitivity of FRET to distance has made it useful for probing distances within 38 nm, for example in the context of protein folding.22-23 FRET can also lead to fluorescence
quenching, a phenomenon that has been applied to proteins containing heme, retinal or other
non-fluorescent chromophores.24-27

1.4. Mass Spectrometry
Mass spectrometry (MS) has evolved as an indispensable tool in proteomics research.
MS represents a weighing balance for ions in the gas phase. Two ionization techniques are
used in proteomics research which allows the transfer of intact protein analytes into the gas
phase under soft conditions. They are referred to as Matrix Assisted Laser
Desorption/Ionization (MALDI-MS) and Electrospray Ionization (ESI).28 These ionization
techniques allow the investigation of compounds with sizes ranging from a few Daltons (Da)
to mega Daltons (MDa).29-30 MALDI was developed in 1985 by Karas and Hillenkamp.31
For MALDI, the analytes are embedded in a solid matrix containing ultraviolet-absorbing
molecules. With the help of a laser pulse, gaseous analyte ions are formed. 32-33 Because ESI

6

is exclusively used throughout this work, the ESI mechanism will be discussed in detail in
the following section.

1.4.1. The ESI Source
ESI is a "soft" technique that is capable of transferring proteins and peptides from
solution into the gas phase. ESI has several advantages over MALDI. ESI can be coupled to
liquid chromatography (LC) which enables on-line separations. ESI generates multiply
charged ions, as opposed to the singly charged ions produced by MALDI. This allows the
detection of large analytes on mass spectrometers with limited m/z range.

Figure 1-2: Schematic representation of an ESI source operated in positive mode
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ESI occurs at atmospheric pressure. An analyte solution is infused into a metal
capillary that is kept at a high voltage (~3kV in positive mode) relative to ground. This high
voltage causes charge separation, where electrons are removed from solution (for example
2H2O→ 4H+ + 4e- + O2). The solution at the tip of the capillary tip gets distorted into a
Taylor cone which emits a mist of µm sized droplets (Figure 1-2).34 The initial droplets
undergo rapid solvent evaporation. The charge density on the shrinking droplets continues to
increase until surface tension equals Coulombic repulsion, also known as the Rayleigh limit.
At this point, the number  of elementary charges e is: 35

 

8
 


1.4

where R is the droplet radius,  is the vacuum permittivity, and  is the surface tension.

Droplets close to  undergo jet fission. Several cycles of evaporation and jet fission

ultimately produce gaseous analyte ions that can be detected by MS.

32-33, 36-37

To avoid the

introduction of droplets and contaminants into the mass analyzer, a counter flow of gas is
used for desolvation (usually N2).38 Nano-ESI is a variant of ESI that requires less sample
volume than regular ESI. Nano-ESI droplets are believed to be at least 10 times smaller than
those produced by regular ESI sources, leading to enhanced salt tolerance.39 This makes
nano-ESI ideal for the study of large protein complexes in electrolyte-containing solutions.
8

The ESI mechanism is widely debated, three scenarios have been put forward to
explain how charged droplets form analytes ions. These are referred to as the charge residue
model (CRM), ion evaporation model (IEM), and chain ejection model (CEM) (Figure 1-3).
37,40-41

The CEM and CRM apply to proteins. The CRM is thought to be operative for native

(compact) proteins.41 The droplet undergoes several evaporation/fission cycles until all the
solvent is removed, leaving a dried out protein ion. Unfolded proteins likely follow the CEM
where the polymer chain exits the droplet with concomitant exchange of mobile charge
carriers (protons).42

Figure 1-3: Summary of protein ESI mechanism for (a) CRM for the transfer of globular
proteins into the gas phase, and (b) CEM used for unfolded proteins.
9

1.4.2. Mass Analyzers
The mass analyzer is used to separate charged analytes ions based on their m/z
values. The charge state of a multiply protonated ion is given by

"⁄  $%  &'



1.5

Ion separation can be achieved by using electric and/or magnetic fields.43-44 Different mass
analyzers, include quadrupoles, time of flight instruments, linear ion traps,

45

Orbitrap,46-48

and Fourier transform ion cyclotron resonance devices.49 Some of these mass analyzers can
be coupled together for tandem MS applications. Only the quadrupole and the time of flight
operation will be discussed in the next section, because they are directly relevant to the
experiments of this work.

1.4.3. Quadrupole Mass Analyzer
The quadrupole is by far the most common mass analyzer. It consists of two pairs of
cylindrical rods with opposite charges (Figure 1-4). With a radio frequency (RF) voltage
applied to the quadrupole, all ions generated in the source can be transmitted to the detector.
In this "RF-only" mode, the quadrupole acts as an ion guide (Figure 1-4b). The quadrupole
can also be used as a mass filter when choosing a combination of direct current (DC) and RF
10

voltages. In this "mass-resolving" mode, only ions with a certain m/z value can pass through
the quadrupole while all other ions collide with the rods because their trajectories are
unstable (Figure 1-4c). Single quadrupoles have been used in early mass spectrometers. In
modern instruments it is more common to use them in conjugation with other analyzers. In
particular Q-TOF instruments use quadrupole for precursor selection in tandem MS.50-54

Figure 1-4: (a) Schematic representation of a quadrupole mass analyzer (b) RF only mode
allows the passage of all analyte ions, and (c) quadrupole in mass filter mode
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1.4.4. Time of Flight (TOF) Mass Analyzer
TOFs are able to separate ions of different m/z values without the need to scan across
the mass range, a feature which is a huge advantage over quadrupole mass filters. In a TOF
instrument, ions are accelerated into a flight tube by the application of a pusher pulse. Upon
acceleration, the potential energy of the ion is converted into kinetic energy, and the time it
takes for the ions to reach the detector can be calculated as follows

)*  +,-

1.6

1
"0 1
2

1.7

/ 

From eq. 1.7, the time it takes to traverse the flight tube by an ion can be calculated as

345

where U, d, m, z and

" 1
 2/

1.8

represent the acceleration voltage, length of the flight tube, mass of

the ion, charge state of the ion, and velocity of the ion, respectively. Equation 1.8 can be
rewritten as:
12
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3  67

1.9

is a parameter independent of the analyte
Where 6  4:
√2/
With conventional TOF instruments, slight deviations in the velocities of ions are not
corrected for, two ions of the same m/z value with slightly different velocities will arrive at
the detector at different times, leading to low mass resolution. The introduction of reflectron
compensates for these velocity differences. Most modern instruments use an orthogonal
acceleration geometry (oa-TOF) where the pusher pulse is applied in a perpendicular
direction towards the incoming ion beam. (Figure 1-5).
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Figure 1-5: Schematic representation of an oaQ-TOF mass spectrometer equipped with a
collision cell for collision-induced dissociation (CID). The red line indicates the ion
trajectory.

The ion travelling with a higher velocity penetrates the reflectron further than one with a
lower velocity. This ensures that the two ions arrive at the detector at the same time leading
to sharper peaks and better resolution.55

1.5. Mass Spectrometry Based Methods for Characterizing Protein
Structure and Dynamics.
1.5.1. Covalent Labeling
14

Covalent labeling is a common approach for examining protein conformations. This
method can probe the solvent accessibility of side chains. Exposed sites react with the
covalent probe very quickly, while buried regions are protected (Figure 1-6).56

Figure 1-6: Schematic representation of a covalent labelling experiment. Solvent accessible
reactive residues become modified (in this case via oxidation) while protected residues
remain unlabeled

Hydroxyl radical (•OH) is a widely used covalent label because it is reactive and
capable of labeling many types of residues. •OH labeling occurs very rapidly with an
estimated time scale of ~1 µs under properly optimized conditions which is useful for
monitoring short lived folding intermediates.57 Quantitative analyses of oxidation patterns (or
solvent accessibility) are usually conducted at the peptide level by subjecting the protein to
enzymatic digestion prior to MS. Single residue resolution has also been reported using LC15

MS/MS methods.58-60 Covalent labeling has been applied to the study of protein-protein
interactions,61-62 protein-DNA complexes,63 integral membrane proteins binding studies64 and
some in vivo experiments.65
Although covalent labeling generates labels that are highly stable and relatively easy
to detect, the analysis is complicated by the fact that differentially labeled peptides do not
coelute during LC. Also, the introduction of covalent labels may alter the protein structure.
This problem can be minimized by ensuring that the number of labels per protein is very
low.66-67

1.5.2. Covalent Cross Linking
Covalent cross linking relies on the ability of two protein side chains, at an
appropriate distance from each other, to undergo coupling upon exposure to a suitable crosslinking agent (Figure 1-7). A variety of cross-linkers have been made, most of consist of two
reactive sites (commonly alkyl chain). Lysines represent the most widely targeted type of
cross-linking site. Cysteine and other residues can be used as well.68 The cross-linking agent
can either be functionalized to probe Lys-Lys distances (homo-bifunctional linkers) or LysCys distances (hetero-bifunctional linkers).
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Figure 1-7: A schematic depiction of a crosslinking reaction, with Lysine residues shown in
red.

Cross-linking agents can also have variable spacer lengths.69 Similar to covalent
labeling, an enzymatic cleavage step is almost always incorporated into the analysis. The
analysis is complicated by the need to separate a small modified peptide fraction from a
largely unmodified digest. This is even more challenging when protein interactions are being
studied because the linker can react in a number of different ways.70

1.5.3. Hydrogen Deuterium Exchange Mass Spectrometry
Hydrogen deuterium exchange (HDX) is a powerful tool for probing the higher order
structures and dynamics of protein.71 HDX coupled with ESI-MS has evolved as a useful
technique for studying the conformation, dynamics and interactions of proteins in solution.7273

HDX measurements can be used to locate binding sites, identify structural changes, and for

distinguishing the populations of protein structures present during exchange.74-75 Different
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studies have used HDX to examine protein-protein and protein-ligand interactions.76-80 HDX
also allows the study of the conformation, dynamics and function of proteins larger than 40
kDa. 81-83
In HDX, protein is exposed to a solvent containing D2O or a fully deuterated protein
is exposed to H2O. The former is known as exchange-in and the latter is referred to as
exchange-out, with both experiments giving identical information. Regions of the protein that
are not involved in hydrogen bonding exhibit a burst phase exchange kinetic, whereas
regions that are in the interior of the protein or involved in hydrogen bonds, exchange at
much slower rates.84 Depending on solvent accessibility and hydrogen bonding strength,
different backbone amide (N-H) hydrogens undergo isotopic exchange at different rates.85
Exchange can also occur at O-H, N-H and S-H sites on the side chains, but these deuteriums
are lost during the LC step due to back-exchange. Thus, the side chains do not contribute to
the measured mass shifts.86 The overall backbone HDX exchange mechanism for native
proteins under continuous labelling conditions can be described as

kop
; < &=>?@A ⇄
kcl

; < &)@-@A

kch
⇄

D2 O

kcl
; < C)@-@A ⇄ ; < C=>?@A
kop

1.10

where kop, kcl, and kch are the opening, closing and chemical exchange rates constants
respectively. Each amide hydrogens in a protein can exhibit a unique combination of kop, kcl
and kch. For exchange to occur in a protected region of the protein, the amide hydrogen of
18

interest has to be solvent accessible which means the hydrogen bonds have to be transiently
broken.87

1.5.4. EX1 and EX2
Two limiting regimes are seen in HDX kinetics for a protein in the native state. They are
EX1 and EX2: EX1 is not common at physiological pH. In this scenario, the chemical
exchange rate is faster than the closing rate (kch >> kcl) (Figure 1-8). The regime can be
promoted in the presence of denaturants and high temperatures. The resulting exchange rate
constant is simply
6ex  6op

1.11

The EX1 regime is characterized by bimodal mass distribution (Figure 1-8)
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Figure 1-8: Deuterium uptake in the EX1 regime

The EX2 exchange regime is usually observed for native proteins at physiological pH where
most labeling experiments take place with kcl>>kch. The exchange rate constant is given by

6HDX 

6op
6ch  Eop6ch
6cl

1.12

where Kop is the equilibrium constant for the opening and closing events. This exchange
regime is manifested via peak envelopes that shift to higher m/z values as the exposure time
increases (Figure 1-9).
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Figure 1-9: Deuterium uptake in the EX2 regime

Finally, for an unfolded protein, the exchange kinetics is only dependent on the chemical
exchange rate constant i.e.

6HDX  6ch

1.13

1.5.5. Effects of Temperature, pH and Composition on Exchange Rate
The exchange rate of N-H hydrogens is dictated by the pH, temperature, solvent
accessibility and hydrogen bonding. As noted, hydrogens in side chain as well as those in the
21

backbone can be exchanged with deuterium. Deuterium in the backbone is retained during
HDX analysis, while side chains back to hydrogen during analysis.88 N-H groups are
catalyzed by acid and base. The rate constant for chemical exchange can be expressed as:

6ch  6H $&+'  6OH $F&-'

1.14

where kH and kOH are rates of acid and base catalyzed exchange respectively. The exchange
rate has a minimum at pH 2.5 - 3. The exchange kinetics are also dependent on temperature
as dictated by the Arrhenius equation as shown below.

GH 6=I  GH < a:J

1.15

1.5.6. General Workflow of HDX-MS Experiments
The general procedure used in HDX-MS is illustrated in Figure 1-10. The experiment can be
conducted at the intact protein level, or in a spatially-resolved manner with protease
digestion.
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Figure 1-10: General protocol for an exchange-in HDX-MS experiment

Isotopic exchange is initiated with the folded protein incubated in D2O buffered to the
desired pH. Aliquots are removed at selected labelling times ranging from a few seconds to
several days. After the deuterium exchange-in step, HDX is quenched by decreasing the pH
to 2.4 and the temperature to 0oC. The intact protein can then be analyzed for global
exchange kinetics. The LCMS analysis is usually carried out within a short time to prevent
back exchange.
To obtain HDX kinetics information on small regions of the protein, the protein is
subjected to proteolysis using an immobilized pepsin column or other acid-active protease
under quench conditions. The use of high pressure during proteolysis can enhance digestion
efficiency.89-90 The resulting peptides are retained on a trapping column before being
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transferred to an analytical column for reverse phase LC to determine the level of deuterium
incorporated in the different segments.88,91 A schematic representation of a state-of-the-art
digestion/desalting and separation fluidic unit for HDX-MS is shown in Figure 1-11.
To avoid carryover in the experiments, washing steps between injections are usually
incorporated into the protocol.92-93 For peptide analysis, MS/MS experiments have to be
carried out first to identify peptides before the actual deuteration experiments. This is
because pepsin is a nonspecific protease which complicates the identification of peptides
after deuteration. The introduction of software packages have helped in minimizing the
problem of peptide analysis in HDX workflows.94-99 Nepenthesin is another acidic protease
that has been used in HDX protocols.100
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Figure 1-2: Layout of a typical fluidics unit for “bottom-up” proteolytic digestion HDX/MS
experiments. (A) Isocratic flow (red) delivered by an auxiliary solvent module (ASM) moves
the protein from the sample loop to a pepsin column for digestion. The resulting peptides are
retained on a short trapping column. (B) Switching of the six-port valve allows the
25

proteolysis products to be washed off the trapping column via flow from a binary solvent
module (BSM) which delivers a water/acetonitrile gradient (blue). The peptides are separated
on a reversed-phase analytical column that is coupled to the ESI source of a mass
spectrometer (MS). Reprinted with permission from Konermann et. al (2014) ACS.97

Back exchange still remains a major problem in HDX-MS experimental protocols.
Back exchange washes out the deuterium pattern incorporated into the protein during the
labelling process.101 This can be mitigated by conducting the digestion and LC workflow in a
short period of time at 0oC. Recent studies have also shown that the use of freezing point
depressants can significantly reduce the amount of back exchange.102,91

1.6. Scope of Thesis
Proteins are not static structures but dynamic systems that undergo fluctuations in
which hydrogen bonds are constantly opened and reclosed. The degree of fluctuation can be
modulated by external stimuli stabilize or destabilize the proteins. Protein-ligand interactions
in HDX experiments usually induce a reduction in the measured HDX rates, and this is
usually ascribed to stabilization of the protein structure.103-104,77
The objective of this research is to improve the understanding of changes in HDX
patterns that are associated with protein-ligand binding. Ultimately, these efforts should
provide insights into protein conformational dynamics, structures, and ultimately function.
Oxy-Hb and aquomet-Hb represent widely used MS test analytes and previous MS
studies have paid little attention to the differences between them by assuming that they both
26

share the same solution phase properties. In Chapter 2, the structural dynamics in oxy-Hb
and aquomet-Hb were compared using HDX-MS. The results indicate a global stabilization
in Oxy-Hb with some destabilization in the heme binding pocket which is a possible
explanation for heme release in aquomet-hemoglobin.
HDX experiments are usually carried out with the expectation that ligand binding will
induce a reduction in the deuteration rates of the protein. In Chapter 3, the effect of ligands
binding to hemoglobin and myoglobin was studied using HDX-MS. This chapter explores
the different scenarios that can be encountered in an HDX experiment upon ligand binding.
The experiments in this chapter suggest that proteins can be globally stabilized or
destabilized after ligand binding. The results further show that it is possible to have both
scenarios in a single protein after ligand binding while some regions of the protein
experience no appreciable change at all.
ClpP is a protease complex responsible for the degradation of substrate proteins in
bacteria. The mechanism of pore opening in ClpP has been a topic of debate in literature with
different views. In Chapter 4, HDX-MS was used to study the interaction between
Caseinolytic Protease (ClpP) an antibacterial drug target and its ligand ADEP. The findings
from this chapter demonstrate that binding of a ligand can trigger conformational changes
both at the binding site and at allosteric sites far from it with hydrophobic interactions
playing a major role at the opening of the ClpP axial pore.
Peptidyl-prolyl isomerases (PPIase) catalyze the cis-trans conversion of X-pro bonds.
Pin 1 is a PPIase involved in cell cycle regulation making it a promising anticancer target. In
Chapter 5, the binding of a cyclic peptide to Pin1 isomerase was monitored using HDX-MS.
27

The experiments in this chapter were able to identify a loop region of residues which may
have been responsible for the inability of researchers to crystalize Pin 1 with its ligands. The
results also indicate that protein ligand interactions can result in both stabilization and
destabilization of the protein structure.
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Chapter 2. Comparative Analysis of Oxy-Hemoglobin and
Aquomet-Hemoglobin by Hydrogen/Deuterium Exchange
Mass Spectrometry
2.1. Introduction
Hemoglobin A (Hb), the oxygen carrier in red blood cells, is among the most thoroughly
studied proteins.1-4 Hereditary Hb defects are associated with anemia and other pathological
symptoms.5 Efforts are currently underway to design chemically modified Hbs for blood
transfusions.6
Hb has a (αβ)2 quaternary structure (Figure 2-1). Each α subunit is closely linked to
one β subunit via a “packing” interface, resulting in two symmetrical heterodimers that are
referred to as α1β1 and α2β2. In comparison, the contacts between α1 and β2 (as well as α2
and β1) are weaker, forming the so-called “sliding” interface.5 O2 transport is mediated by
allosteric switching between the oxy (R) and deoxy (T) states. In oxy-Hb the distal
coordination sites of all four heme iron centers are occupied by O2, whereas in the deoxy
state these sites are vacant. During the R-T transition α1β1 rotates by 15° relative to α2β2.
Interactions across the sliding interface are less extensive in R, whereas T is stabilized by
additional salt bridges.1-5 O2 binding is only possible if the heme iron is in the 2+ state.
Autooxidation to Fe(3+) can take place under physiological stress, but also during protein
isolation and storage. The aquomet-Hb generated in this way is dysfunctional and has the
distal iron coordination sites occupied by water.7 Aquomet-Hb formation in vivo causes a
weakening of the heme-protein interactions. This facilitates release of Fe(3+) heme from the
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protein and diffusion of the porphyrin into lipid membranes where it can trigger oxidative
damage. Existing data provide little insights as to why heme dissociation from aquomet-Hb is
more facile than from oxy-Hb.8

Figure 2-1: X-ray structure of bovine Hb (carbon monoxide-bound Fe(2+) state, pdb file
2qss 8). The subunit numbering follows the commonly used notation 1. Heme groups are
shown in magenta. The sites of distal ligand binding to the heme iron (oxygen in oxy-Hb, and
water in aquomet-Hb) are highlighted in red.
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Although the properties of Hb have been explored in great detail,

1-5

there are still

major gaps in the general understanding of this protein.4-9 New X-ray investigations revealed
a host of conformations that differ from the canonical T and R states. The functional
significance of these newly discovered conformers remains unclear.9-12 Wide-angle X-ray
solution scattering13 and NMR spectroscopy14-15 point to marked differences between Hb in
solution and in the crystallized state. As a result, many aspects related to Hb structure and
function are more controversial today than they were 30 years ago.13
In addition to its central biomedical role, Hb represents an important test system for
the development of novel bioanalytical techniques. Mass spectrometry (MS), in particular,
relies heavily on Hb as model protein.16-17 A key milestone was the development of “native”
electrospray ionization (ESI)-MS for studies on intact Hb18-20 and other protein complexes.2123

Those early successes18-20 paved the way for subsequent Hb dissociation experiments, ion

mobility studies, and gas phase isotope exchange investigations.24-29 On-line ESI-MS has
been used for probing Hb subunit interactions, highlighting the potential of this approach for
monitoring self-assembly processes in solution.30-33 Desorption ESI (DESI)-MS34 and matrixassisted laser desorption/ionization (MALDI)-MS

35

investigations routinely use Hb for

benchmarking purposes. The prevalence of Hb as a MS model system is due to the fact that
the protein is readily available at low cost. Also, existing X-ray data

1-5,12

provide a

comprehensive reference base for the development of MS-based structural biology tools.
Backbone amide hydrogen/deuterium exchange (HDX) coupled with ESI-MS has
become a widely used method for studying protein behavior in solution.36-38 Polypeptide
regions that exhibit a high degree of conformational dynamics undergo rapid exchange,
whereas HDX in rigid hydrogen-bonded segments is much slower. HDX/MS measurements
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commence with protein exposure to a D2O-containing solvent. Aliquots taken at selected
labeling times are quenched at acidic pH. Pepsin digestion and subsequent peptide analysis
by liquid chromatography (LC)/ESI-MS are carried out at low temperature. Spatiallyresolved HDX kinetics can then be obtained by tracking the mass shifts of individual
peptides.
Of the three Hb forms mentioned above, only oxy-Hb and aquomet-Hb represent
widely used MS test analytes.16-20,24-26,28-35 In contrast, MS investigations on deoxy-Hb are
rare because they require an O2-free environment.39 Previous MS studies paid little attention
to possible differences between oxy-Hb and aquomet-Hb, implicitly assuming that both share
the same solution phase properties. This view is consistent with X-ray data, according to
which oxy-Hb and aquomet-Hb crystallize in virtually identical conformations. Depending
on the conditions, this common structure can be either the R state,5,40-41 or a conformation
that is referred to as R2.42-43 Close examination of oxy and aquomet-Hb crystal structures
reveals only small differences related to the iron positioning within the heme.5-44
Nonetheless, it remains unclear in how far those X-ray data 5,40-44 provide solid evidence for
the notion that oxy-Hb and aquomet-Hb exhibit the same structural and dynamic behavior in
solution. It is also noted that there are no crystallographic investigations that employed dilute
ammonium acetate which serves as de facto standard solvent for MS studies on Hb.18-19,2425,28-35

HDX/MS represents an obvious strategy for probing possible differences in the
solution phase properties of the various Hb forms. Earlier HDX work examined the
relationship between the oxy and deoxy states.39,45-46 The latter exhibits a higher degree of
protection, consistent with the more rigid structure of the T conformation.1-4 Surprisingly,
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there appear to be no prior HDX/MS-based comparative analyses of oxy-Hb and aquometHb. The goal of the current work is to close this gap. Despite the fact that oxy-Hb and
aquomet-Hb adopt virtually the same crystal structures

5,40-44

, our HDX/MS data reveal that

their solution phase behavior exhibits significant differences.

2.2. Experimental Procedures
2.2.1. Materials
Porcine pepsin and potassium ferricyanide were purchased from Sigma (St. Louis, MO,
USA). Ammonium acetate was obtained from Fluka (St. Louis, MO, USA). D2O was from
Cambridge Isotope Laboratories (Andover, MA). All chemicals were used as received. OxyHb was isolated from fresh bovine blood following established procedures,7-32 and stored at 80 °C until further use. Protein concentrations are reported on a per-tetramer basis throughout
this work. Hb solutions for all experiments contained 10 mM ammonium acetate. AquometHb was produced by exposing oxy-Hb to excess potassium ferricyanide, followed by
desalting on a size exclusion column.32 The level of covalent modifications due to side chain
oxidation was found to be negligible for the protein samples used here, as reported
previously32 (data not shown). The measured mass values of the two subunits were consistent
with those calculated from the sequence of bovine Hb8, i.e., (15,053 ± 1) Da for α and
(15,954 ± 1) Da for β. UV-Vis absorption spectra were recorded on a Cary 100 instrument
(Varian, Mississauga, ON, Canada). pH values were measured using a Fisher (Waltham,
MA) AB15 pH meter; these values are reported without isotope correction.
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2.2.2. Hydrogen/Deuterium Exchange Mass Spectrometry
150 µM Hb (in the oxy or aquomet states) in 10 mM ammonium acetate was mixed with 4
volumes of D2O containing 10 mM ammonium acetate, resulting in a protein concentration
of 30 µM with a measured pH of 7.2 at room temperature. 30 µL aliquots were removed at
various time points ranging from 1 to 360 min after initiating labeling. The aliquots were
quenched at pH 2.4 by addition of HCl on ice, followed by flash freezing in liquid nitrogen
and storage at -80 oC. For digestion, the aliquots were rapidly thawed to ~0 oC and mixed
with 5 µL pepsin stock solution (1 mM in aqueous acetic acid, pH 4.1) at pH 2.4 for 1 min on
ice. The final Hb concentration was 20 µM. The resulting peptic fragments were desalted and
separated within 15 min on an equilibrated reversed phase column (Jupiter 4 µ Proteo, C12,
50 × 1 mm; Phenomenex, Torrance, CA) with an online prefilter (KrudKatcher;
Phenomenex) coupled to a Waters UPLC pump at a flow rate of 100 µL min-1, using a
water/acetonitrile gradient in the presence of 0.1% formic acid. The injection loop volume
was 20 µL and the total amount of protein per injection was 400 pmol. The injection syringe,
column, injector and solvent delivery lines were kept at ~0 °C. Mass analysis of peptides was
performed on a Synapt HDMS instrument (Waters, Milford, MA) with source and
desolvation temperatures of 80 and 300 °C respectively, a cone voltage of 30 V, and an ESI
voltage of 3 kV. The identity of each peptide was confirmed by tandem MS based on the
known sequence of bovine Hb (pdb code 2QSS 8). Zero time point controls (m0) for the
correction of artifactual in-exchange were performed by exposing Hb to a mixture of D2O
and quenching buffer, using the solutions described above. Controls for fully exchanged Hb
(m100, for the correction of artifactual back exchange) were prepared by incubating 30 µM Hb
in labeling solution at pH 2.4 for 9 h. Intact protein HDX measurements were performed
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using a procedure similar to that described above, but by using a different column (Jupiter 5
µm Proteo, C4, 50 mm × 1mm; Phenomenex) without pepsin digestion. Biolynx 4.1
(Waters), HX-Express 47 and manual inspection were employed to analyze the centroid mass
of all peptides as a function of labeling time. Deuteration levels were determined as

% Deuteration =

( m − m0 )
( m100 − m0 )

(2.1)

All HDX measurements were conducted in triplicate; error bars shown in the figures below
correspond to standard deviations.

2.3. Results and Discussion
2.3.1. Optical Characterization of Hb Samples
Prior to conducting MS experiments it is important to verify the properties of the protein
samples. The UV-Vis absorption spectrum of Hb represents a sensitive probe of the heme
oxidation and ligation state (Figure 2-2). After thawing, Hb samples obtained from fresh
bovine blood exhibit an absorption spectrum with a dominant Soret signal at 415 nm, along
with bands at 541 and 577 nm. The presence of these so-called γ, β, and α signals represents
the hallmark of oxy-Hb.7
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Figure 2-2: UV-Vis absorption spectra of oxy-Hb and aquomet-Hb in 10 mM ammonium
acetate. The protein concentration was 3 µM for both samples. Differences in the intensity of
the Soret peak are caused by the different molar absorption coefficients of the two forms 7.

After ferricyanide treatment the bands at 541 and 577 nm disappear and the Soret maximum
shifts to 405 nm, as expected for Fe(3+) with distal iron coordination by water.7,32 These
spectral data confirm the authenticity of the oxy-Hb and aquomet-Hb samples used in this
work.

2.3.2. Global HDX Kinetics
For comparing the solution phase behavior of oxy-Hb and aquomet-Hb, HDX/MS
measurements were initially conducted on the intact subunits. Markedly different isotope
exchange kinetics are observed for the oxy and aquomet forms (Figure 2-3). Throughout the
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6 h experimental time window the deuteration levels of aquomet-Hb are higher (by up to
10%) than those of oxy-Hb. These differences extend to both subunits. Clearly, the oxy 
aquomet transition induces a conformational destabilization, resulting in more pronounced
conformational dynamics for aquomet-Hb than for oxy-Hb. This is despite the fact that both
forms crystallize in virtually the same conformation. 5,40-43
As noted in the Introduction, previous investigations demonstrated that deoxy-Hb
exhibits lower HDX levels than oxy-Hb 39,45-46. That behavior is consistent with the presence
of more extensive contacts across the sliding interface in deoxy-Hb relative to oxy-Hb.1-5
Those different subunit interactions are reflected in the tetramer-dimer dissociation constant
(Kd) which is 2 × 10-6 M for oxy-Hb, and <10-10 M for deoxy-Hb

8,48

. It might be expected

that the enhancement of conformational dynamics seen in Figure 2-3 upon oxy  aquomet
conversion is also related to changes in interaction strength at the sliding interface. However,
the dissociation constants of aquomet-Hb and oxy-Hb are indistinguishable.32 We therefore
conclude that the enhanced dynamics seen for aquomet-Hb relative to oxy-Hb must be
caused by an internal destabilization of the α1β1 and α2β2 units, rather than additional
weakening of the sliding interface.
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Figure 2-3: HDX kinetics of aquomet-Hb (open symbols) and oxy-Hb (filled symbols). The
two panels show data for the intact α (top) and β subunits (bottom) of the tetramer. Lines
represent biexponential fits according to eq. 2.2.
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2.3.3. Spatially-Resolved HDX/MS Measurements
A more detailed view of the protein dynamics in the oxy and aquomet states is obtained when
analyzing the HDX kinetics at the peptide level. Peptic digestion of Hb yielded 30 fragments
that had a sufficiently high signal-to-noise ratio for reliable deuteration measurements. The
overall sequence coverage obtained in this way is 82% (Figure 2-4). Exchange occurs in the
EX2 regime, evident from a lack of peak splitting in the isotope envelopes (data not shown).
As expected from the intact protein data (Figure 2-3), most peptides exhibit higher HDX
levels for aquomet-Hb than for oxy-Hb throughout the experimental time window (Figure 25). However, there are several regions that display almost the same kinetics in both states
(such as β7-13); a few peptides even show the opposite trend (α1-23, α67-80, α110-125, and α129136).

This pattern reveals that the overall destabilization accompanying the oxy  aquomet

transition does not affect all regions of the Hb tetramer to the same extent.
Many features of the measured HDX kinetics in Figure 2-5 are consistent with
crystallographic data.8 Peptides that comprise helical regions generally show significant
protection. For example, α99-106 and β102-109 exhibit the lowest deuteration levels, in line with
their positioning in the central regions of helices αG and βG, respectively. By the same
token, some of the most highly deuterated peptides such as α47-53 , α135-141, β1-8, and β41-47
correspond to loops and termini that are expected to be relatively mobile. Interestingly,
several other peptides show very limited protection, despite being located in regions that
appear to be tightly folded in crystallized Hb.8 One of these is α119-125, suggesting that the
αG-αH loop comprises more residues than seen in the X-ray structure.
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Figure 2-4: Sequence of the Hb α and β subunits. Helices are denoted as rectangles. Peptic
fragments are indicated below the sequence. Solid lines represent peptides used for data
analysis, whereas dashed lines represent redundant fragments. Boxes above the sequence
indicate helices.
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Similarly, the high HDX levels of β7-13 indicate considerable fraying at the N-terminus of
helix βA. Our data therefore support the view 13-15 that not all of the structural features seen
in crystallized Hb adequately reflect the solution-phase behavior.
To facilitate the discussion of the measured HDX data, deuteration percentages were
mapped to the X-ray structure of the Hb subunits for t = 120 min (Figure 2-6a-d).
Overlapping peptides can be used to approximate the HDX behavior of segments that do not
directly correspond to proteolysis products.49 This case applies to peptides α107-125 and α119-125
that exhibit 41% and 99% deuteration, respectively, in oxy-Hb.
Thus, the average deuteration percentage of α107–118 can be estimated as [16×41% 5×99%] / 10 = 16%. This calculation takes into account the presence of prolines, as well as
deuterium loss on the first two residues of each peptide.50 The adjacent peptide α99–106 shows
an even lower deuteration level of 7%, thereby pinpointing helix αG as the most protected
element in the α subunit (residues 99 – 118, blue in Figure 2-6a). Similarly, βG represents
the most protected helix in the β subunit (green, Figure 2-6b). The four G helices retain high
protection even after the oxy  aquomet transition (Figure 2-6c, d). The low deuteration
levels are consistent with the role of αG and βG as deeply buried elements that
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Figure 2-5: HDX kinetics of peptides covering the α and β subunits of aquomet-Hb (open
symbols) and oxy-Hb (filled symbols). Residue numbers of the individual peptides are
indicated in each panel. Lines are biexponential fits of the form
% Deuteration = A0 + A1 (1 − e − k1t ) + A2 (1 − e − k2t ) where A0 is the fraction of amide backbone
groups that undergoes burst phase labeling, and A1 and A2 are the fractions that undergo
deuteration with apparent rate constants k1 and k2, respectively.
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Figure 2-6: Mapping the HDX data of Figure 2-5 to the X-ray structure of bovine Hb 8 for t
= 120 min. Using the orientation of Figure 2.1 as reference, the top row of panels in this
Figure corresponds to α1, the bottom row represents β2. Colors in (a) - (d) represent
deuteration percentages, as defined in the legend along the bottom. Gray elements in (a) - (d)
were not covered by peptide mapping. Panels (e), (f): Deuteration differences, calculated as
[aquomet - oxy] for t = 120 min. Colored regions correspond to |difference| > 5%. Segments
that show elevated deuteration after oxy  aquomet conversion are depicted in red.
Segments with reduced deuteration are shown in blue. In all six panels the ligand binding site
on the heme is highlighted in cyan.

form key anchoring points at the packing interface.8 Two other regions are quite
highly protected in oxy-Hb, i.e., the central portions of αB and αH (green, Figure 2-6a).
The last two panels of Figure 2-6 highlight the deuteration differences upon oxy 
aquomet conversion. Segments that show enhanced conformational dynamics are depicted in
red, those that undergo rigidification are shown in blue. It is seen that changes in the β
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subunit are not restricted to specific regions. Instead, the whole polypeptide chain
experiences a global destabilization (Figure 2-6f). In contrast, α globin shows a more
intricate behavior where enhancements in structural dynamics are largely confined to the
vicinity of the heme (Figure 2-6e, red). The location of these red elements in Figure 2-6e is
consistent with the expectation that the heme binding pocket should be the epicenter of any
structural changes that accompany the transition from the Fe(2+)…O2 state to the
Fe(3+)…H2O form. Interestingly, helix αA as well as a number of adjoining regions become
stabilized after aquomet formation (Figure 2-6e, blue). These stabilized regions in the α
subunit are more remote from the heme, and they are not heavily involved in inter-subunit
contacts. Overall, Figures 2-6e and 2-6f reveal that α and β globin respond to the oxy 
aquomet conversion in a very different fashion. This behavior is surprising, when considering
the very similar average conformations of α and β, their symmetrical positioning within the
Hb tetramer, and their high sequence homology.8

2.4. Conclusions
To the best of our knowledge, this is the first HDX/MS investigation that compares the
conformational dynamics of oxy-Hb and aquomet-Hb. The two forms adopt virtually the
same crystal structures, yet they exhibit solution-phase dynamics that are clearly different.
Our findings are consistent with earlier studies that noted limitations in the predictive power
of crystallographic data for protein behavior in solution. 13-15,51
Aquomet-Hb is known to show elevated rates of heme loss relative to oxy-Hb,
although the reasons underlying this behavior remain incompletely understood. Heme loss is
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of biomedical significance, because free Fe(3+) heme can incorporate into lipid membranes,
thereby triggering oxidative damage.8 This process is of particular relevance after hemolysis,
where oxy-Hb or deoxy-Hb are released from red blood cells. Binding to haptoglobin is a
mechanism for sequestering free Hb in the blood plasma, thereby counteracting aquomet-Hb
formation and heme release.52 Nonetheless, under some conditions there can still be free Hb
molecules that undergo autooxidation to the Fe(3+) state.53 We propose that the enhanced
structural dynamics observed here for aquomet-Hb are a key factor that facilitates Fe(3+)
heme dissociation from the protein. It is likely that the enhanced structural dynamics in the
heme binding pocket of α globin (red in Figure 2-6e) directly reflect the adverse effects of
aquomet formation on the stability of the heme-protein interactions.
Finally, we note that one of the most intriguing questions in biological MS is to what
extent supramolecular solution phase structures can be preserved upon transfer into the gas
phase.54-57 Investigations targeting this issue typically rely on crystallographic data as
surrogate for the actual solution phase structure of the system under investigation. As
discussed above, this strategy is not always adequate.13-15,51 The special role of oxy-Hb and
aquomet-Hb as widely used model analytes in MS

16-20,24-35

warrants a close examination of

their solution phase properties. In contrast to information provided by static X-ray data,5,40-43
our HDX/MS results demonstrate that the solution phase dynamics of the two forms exhibits
marked differences. It is hoped that the observations of this work will benefit future
investigations on the relationship between Hb behavior in solution and in the gas phase.
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Chapter 3. Effects of Protein-Ligand Interactions on
Hydrogen/Deuterium Exchange Kinetics: Canonical and NonCanonical Scenarios

3.1. Introduction
Hydrogen/deuterium exchange (HDX) methods are widely used for monitoring proteinligand interactions. This approach relies on the fact that ligand binding can modulate the
extent of protein structural fluctuations that transiently disrupt hydrogen bonds and expose
backbone amides to the solvent. It is commonly observed that ligand binding causes a
reduction of HDX rates. This reduction may be restricted to elements adjacent to the binding
site, but other regions can be affected as well. Qualitatively, ligand-induced HDX protection
can be rationalized on the basis of two-state models that equate structural dynamics with
global unfolding/refolding. Unfortunately, such models tend to be unrealistic because the
dynamics of native proteins are dominated by sub-global transitions and local fluctuations.
Ligand binding lowers the ground state free energy. It is not obvious why this should
necessarily be accompanied by a depletion of excited state occupancies, which would be
required for a reduction of HDX rates. Here, we propose a framework which implies that
ligand binding can either slow down or accelerate amide deuteration throughout the protein.
These scenarios are referred to as “type 1” and “type 2”, respectively. Evidence for type 1
binding is abundant in the literature, whereas the viability of type 2 interactions is less clear.
Using HDX mass spectrometry (MS) we demonstrate that the oxygenation of hemoglobin
(Hb) provides a dramatic example of a type 2 scenario. The observed behavior is consistent
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with cooperative T → R switching, where part of the intrinsic O2 binding energy is
reinvested for destabilizing the ground state. This destabilization increases the Boltzmann
occupancy of unfolded conformers, thereby enhancing HDX rates. Surprisingly, O2 binding
to myoglobin (Mb) also induces elevated HDX rates. These Mb data reveal that type 2
behavior is not limited to cooperative multi-subunit systems. Although enhanced protection
from deuteration is widely considered to be a hallmark of protein-ligand interactions, this
work establishes that an overall deuteration increase also represents a viable outcome. HDXbased ligand screening assays, therefore, have to allow for canonical as well as non-canonical
effects.

Numerous biological processes and drug action mechanisms are mediated by noncovalent
protein-ligand binding. The affinity of these interactions ranges from millimolar to subpicomolar Kd values, with dissociation free energies that are given by ∆dG° = -RT ln Kd. For a
protein P and its ligand L the dissociation constant is defined as Kd = [P][L]/[PL]. The
magnitude of ∆dG° is governed by a complex interplay of entropic and enthalpic factors, with
contributions originating from the protein, the ligand, and the solvent.1-3 Methods for
predicting protein-ligand affinities are still in their infancy,4-5 largely because enthalpyentropy compensation effects and related issues remain poorly understood.6-11
Isothermal titration calorimetry (ITC) is widely used for exploring thermodynamic
aspects of protein-ligand interactions.2 Binding can also be explored in titration studies with
optical, NMR,12 or mass spectrometric detection.13-14 Nonetheless, there remains a need for
improved strategies that are capable of probing thermodynamic and structural aspects of
protein-ligand systems. Areas that will benefit from such initiatives include the screening of
drug candidates, as well as epitope mapping applications.15-16
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Hydrogen/deuterium exchange measurements (HDX) with mass spectrometry (MS)1722

or nuclear magnetic resonance (NMR) spectroscopic detection23-32 have gained a strong

foothold for protein-ligand binding studies. Exposure of a protein to a D2O-based solvent
induces the replacement of backbone amide hydrogens with deuterium. Most backbone N-H
groups in natively folded proteins are engaged in hydrogen bonds. Deuteration at these sites
is mediated by thermally activated opening/closing fluctuations that transiently rupture
hydrogen bonds and expose N-H groups to the solvent.33 The exchange mechanism can be
expressed as34

N − H closed

kop

→
← 
kcl

N − H open

kch
→
D 2O

exchanged

(3.1)

where the opening and closing rate constants are designated as kop and kcl, respectively, and
where kch is the chemical rate constant.35
HDX experiments are generally conducted with the expectation that ligand binding
will induce a reduction in deuteration rates, a view that is based on a large body of prior
MS17-22 and NMR23-32 work. This widely held paradigm implies that ligand-bound systems
will tend to be “more tightly folded”, and hence more resilient towards structural fluctuations
of the type described in eq 2.1. A multitude of protein-ligand systems behave in accordance
with this canonical scenario,17-20,22-32,36-37 consistent with the fact that intermolecular binding
is often accompanied by the formation or the strengthening of intramolecular bonds.38-39 In
favorable cases this ligand-induced HDX protection is most pronounced for regions that
directly interact with the ligand. However, this is not always the case,40-41 e.g., when the
binding mechanism involves allosteric elements.17-18,26,42
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Interestingly, it appears that ligand binding can have stabilizing as well as
destabilizing effects on the protein structure.43 For example, there are instances where ligand
binding decreases deuteration rates only in some regions of the protein, whereas other
regions display more extensive HDX.42,44-46 Related differential effects have been reported on
the basis of neutron scattering experiments,47 computer simulations,48 and NMR spin
relaxation measurements.3,9 J-coupling experiments have highlighted the possibility that
ligand binding can induce a buildup of strain in some regions of a protein, evident from an
elongation of certain backbone hydrogen-bonds.49
The preceding considerations call into question the view that protein-ligand
interactions are generally associated with reduced deuteration rates. The current work goes
one step further, and asks if it is possible that ligand binding can sometimes cause an overall
HDX acceleration. We show that such a scenario is indeed feasible. Using hemoglobin (Hb)
and myoglobin (Mb) as examples, we illustrate the entire range of possible outcomes – from
strongly reduced (“type 1”) to strongly increased deuteration rates (“type 2”). We propose a
model that links the different types of ligand binding effects to alterations in the Boltzmann
occupancy of partially unfolded conformers.

3.2. Materials and Methods
3.2.1. Proteins and Reagents.
Horse heart met-(FeIII)-Mb and sodium dithionite (NaS2O4) were purchased from Sigma (St.
Louis, MO). Na2HPO4, NaH2PO4, and NaCl were from Caledon (Georgetown, ON, Canada),
and D2O was procured from Cambridge Isotope Laboratories (Andover, MA). Protein
solutions for all experiments contained 50 mM phosphate buffer, as well as 20 mM NaCl or
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10 mM sodium dithionite. Apo-Mb was prepared using butanone extraction.50 Deoxy-(FeII)Mb was prepared by exposing met-Mb to 10 mM dithionite under nitrogen at neutral pH.51
Deoxy-Mb was then converted to oxy-Mb by the introduction of air followed by dithionite
removal on a G-25 Sephadex size exclusion column (Sigma) that was eluted with 10 mM
aqueous ammonium acetate. Subsequently, the protein was dialyzed against 50 mM
phosphate buffer containing 20 mM NaCl. Oxy-Hb was isolated from fresh bovine blood as
described previously.52 Deoxy-Hb was prepared by exposing oxy-Hb to 10 mM sodium
dithionite and deoxygenation under nitrogen.53 UV-Vis absorption spectra were recorded on
a Cary 100 instrument (Varian, Mississauga, ON, Canada). The different heme oxidation and
ligation states produced by the procedures outlined above give rise to characteristic UV-Vis
absorption spectra that are consistent with reference data from the literature (Figure 3-1).54
pH values were measured using a Fisher (Waltham, MA) AB15 pH meter, these values are
reported without isotope correction.
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Figure 3-1: (a) UV-Vis absorption spectra of different Mb derivatives (oxy, deoxy, and met)
at pH 7. (b) UV-Vis spectra of oxy- and deoxy-Hb. Also shown in both panels are spectra of
the deoxy proteins after 2h of HDX with repeated removal of aliquots.

3.2.2. Hydrogen/Deuterium Exchange Mass Spectrometry.
50 µM protein (in the apo, oxy or deoxy states) in 50 mM sodium phosphate buffer
containing 20 mM NaCl or 10 mM sodium dithionite was mixed with 9 volumes of D2O
containing the same buffer and salt concentrations as the stock, resulting in a protein
concentration of 5 µM with a measured pH of 7.2 at room temperature (22 °C). 30 µL
aliquots were removed at various time points ranging from 1 to 120 minutes after initiation of
labeling. UV-Vis experiments confirmed that the deoxy-samples remained de-oxygenated
throughout the experiment (Figure 3-1). The aliquots were quenched at pH 2.4 by addition of
HCl on ice, followed by flash freezing in liquid nitrogen and storage at -80 °C. The aliquots
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were rapidly thawed to ~0 °C and manually injected into a nanoACQUITY UPLC with HDX
technology (Waters, Milford, MA)55 for desalting and peptide separation within 15 min on an
equilibrated reversed phase column (BEH C18 1.7 µm, 1 mm × 100 mm) using a
water/acetonitrile gradient in the presence of 0.1% formic acid at 35 µL min-1. Online
digestion was performed using a POROS pepsin column (2.1 mm × 30 mm) from Life
Technologies/Applied Biosystems (Carlsbad, CA) at 15 °C. The temperature for peptide
trapping and reversed phase separation was set to 0 °C. Blank (water) injections were
performed in-between protein injections to eliminate carryover. Peptide mass analysis was
performed on a Waters Synapt HDMS instrument with source and desolvation temperatures
of 80 and 300 °C, respectively, a cone voltage of 30 V, and an electrospray voltage of 2.8
kV. The identity of each peptide was confirmed by tandem MS based on the known
sequences (Figure 3-2 and 3-3).

Figure 3-2: Peptic cleavage map of Mb. Solid lines represent peptides used for data analysis,
and dashed lines represent redundant fragments. Helices are indicated by boxes
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Figure 3-3: Sequence of the Hb α and β subunits. Solid lines represent peptides used for data
analysis, and dashed lines represent redundant fragments. Helices are indicated by boxes.

Zero time point controls (m0) for the correction of artifactual in-exchange were
performed by exposing the proteins to premixed D2O and quenching buffer, using the
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solutions described above. Fully exchanged control samples (m100, for the correction of
artifactual back exchange) were prepared by incubating 5 µM protein in labeling solution at
pH 2.4 for 9 h (Hb) or 48 h (Mb). For measuring HDX kinetic profiles the centroid mass of
all peptides as a function of labeling time was determined using HX-Express(Figure 3-4 and
3-5).56
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Figure 3-4: HDX kinetics of peptides covering the sequence of Mb showing deoxy-Mb
(open black circles) and oxy-Mb (filled circles). Residue numbers of the individual peptides
are indicated in each panel. Also shown are data acquired for apo-Mb (filled red triangles).
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Figure 3-5: HDX kinetics of peptides covering the α and β subunits of oxy-Hb (filled
symbols) and deoxy-Hb (open symbols). Residue numbers are indicated in each panel. Lines
are biexponential fits.

The resulting data are reported as % Deuteration = (m-m0)/(m100-m0). Intact protein
HDX/MS was conducted without using the integrated HDX module. Protein separation was
performed on a C4 column (BEH300 C4 1.7 µm, 2.1 mm × 50 mm) at a flow rate of 200 µL
min-1. The injection loop volume was 20 µL and the total amount of protein per injection was
100 pmol. The injection syringe, column, injector and solvent delivery lines were kept at 0
°C in an ice bath. All measurements were conducted in triplicate; error bars represent
standard deviations.
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3.3.

Results and Discussion

3.3.1. Thermodynamic Considerations.
Prior to discussing experimental data, it is necessary to examine the connection
between

ligand

binding

and

HDX

kinetics.

Under

EX2

conditions

(kcl >> kch) the deuteration rate constant kHDX of a backbone N-H within the framework of eq
2.1 can be expressed as
kHDX = pop kch

(3.2)

where pop is the fraction of time that the site spends in the open state.33 A lowering of kHDX
does not necessarily imply that the protein becomes “more rigid” in the sense that it loses
conformational entropy, has less extensive RMS fluctuations, or slows down its closed ↔
open interconversion. Instead, according to eq 2 the only unambiguous conclusion that can
be drawn from a reduced EX2 rate is that amides spend less time in the open state.
Using Boltzmann statistics,57 pop can be calculated according to

pop =

e

−

∆ op G °
RT

Z

(3.3)

where ∆opG° is the opening free energy and Z = 1 + exp(-∆opG°/RT) is the partition
function.58 For a stable protein kcl >> kop, such that ∆opG° >> 0 and Z ≈ 1. [ Note that One can
define an opening equilibrium constant Kop = exp(-∆opG°/RT), such that eq 2.2 turns into the
well-known expression kHDX = Kop kch. For interpreting protein-ligand interactions it is
advantageous to use an alternative approach that retains the exponential notation of eq 2.3.]
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The occupancy of the closed state is 1/Z ≈ 1. When expressing free energy in RT units (∆opG°
= ∆j × RT) the excited state occupancy becomes pop = exp(-∆j) such that

kHDX = e - ∆j kch

(3.4)

We will first discuss ligand binding effects for a hypothetical two-state protein that
undergoes conformational fluctuations between its native (N) and unfolded conformation
(U). This textbook approach (Figure 3.6)22,59 envisions that N can form a complex NL,
whereas U is incapable of ligand binding. Opening/closing transitions (eq 1) are equivalent to
global unfolding/refolding for this two-state system. We arbitrarily assume that in the
absence of ligand ∆opG° = 4 RT, such that pop = e-4 (Figure 3-6A). Figure 3-6B illustrates
what happens when ligand binding lowers the standard free energy of the ground state by
∆dG° = 2 RT. This widening of the free energy gap changes pop from e-4 to e-6, thereby
reducing kHDX (eq 2.4). This example demonstrates that alterations of excited state
occupancies are key to understanding ligand binding effects in HDX studies.
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∆opG°

N

∆dG°
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Figure 3-6: Free energy level diagram of a two-state protein that can bind a ligand L in the
ground state only. (A) No ligand present. U (open) is separated from the ground state N
(closed) by 4 RT, resulting in an excited state occupancy of e-4. (B) Ligand binding widens
the gap between U and the new ground state NL to 6 RT. The excited state occupancy drops
to e-6 and kHDX decreases according to eq 3.4.

Unfortunately, the two-state model of Figure 3-6 represents an oversimplification
(except for special cases33). Under realistic conditions the opening/closing dynamics of
proteins are dominated by a multitude of sub-global events such as foldon fluctuations,
fraying, and local dynamics down to the individual amide level.33,36,60-61 Most of these
spatially confined events can proceed without dissociation of the PL complex. It is not
obvious, therefore, why ligand binding should always widen the free energy gaps between
the ground state and partially unfolded conformers. In other words, it seems unjustified to
expect that binding will generally decrease kHDX. A closer examination of this issue requires a
refined model.
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Figure 3-7: Free energy level diagram of a protein that can adopt many partially unfolded
ligand-bound states. Only three of these are shown. The Boltzmann occupancy of each state
is exp(-∆j). Ligand binding lowers the free energy of the ground state by ∆dG°. (A) No ligand
present. Excited states are assumed to be ∆j = 5, 7, and 9 RT units above the ground state; (B)
Type 1 scenario, where ligand binding lowers HDX rates. Excited state populations are
reduced relative to (A), and kHDX decreases. (C) Type 0 scenario, where excited state
populations and HDX kinetics remain unchanged after binding. (D) Type 2 scenario, where
excited state populations are increased such that deuteration proceeds more rapidly after
binding. The overall binding affinity in (D) is determined by two competing contributions (eq
3.5).

Figure 3-7A schematically illustrates the many thermally excited states that are
accessible to a ligand-free protein under native solvent conditions. Each of these excited
levels (only three are shown to prevent clutter) represents a conformation where a certain
subset of amides is open, whereas the ground state N is all-closed. The occupancy of each
level is given by eq 3.3, with the caveat that the partition function now becomes Z = 1 + Σ
exp(-∆j) where the sum extends over all possible conformers. Nonetheless, the
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approximation Z ≈ 1 still holds because kcl >> kop.23,24 This implies that the occupancy of
each excited state can still be expressed as p = exp(-∆j), and that eq3.4 remains valid. Ligand
binding will shift the free energy levels of the ground state, as well as those of the partially
open conformers. We will have a look at three conceivable types of outcomes, all of which
are scaled such that the NL ground state corresponds to ∆j = 0.
Type 1: Ligand binding lowers the free energy of NL by ∆dG° (chosen to be 4 RT in
Figure 3-7B). Protein-ligand contacts cause a strengthening of intramolecular bonds via
entropic cooperativity and local concentration effects.59 As a consequence, transitions to
excited conformers are associated with wider free energy gaps (larger ∆j values) than in the
absence of ligand. The lower occupancy of partially unfolded conformers causes a decrease
of HDX rates, as dictated by eq 3.4.
Type 0: A ligand binds with the same affinity as in the previous case (∆dG° = 4 RT),
but in a fashion that has only very minor effects on the internal energy landscape of the
protein. For example, the ligand might interact with a solvent-exposed side chain.62 In this
case all of the excited conformations will shift down by the same amount ∆dG° as the NL
ground state. The ∆j values under these conditions will remain the same as for the ligand-free
case. Hence, ligand binding will cause no change in the HDX kinetics (Figure 3-7C).
Type 2: We consider a protein with a binding site that possesses a large intrinsic
affinity ∆dG°intr. However, the ligand can only be accommodated in the NL ground state after
an unfavorable structural change has taken place. This conformational switching event is
associated with a free energy “penalty” termed ∆G°switch. The overall binding affinity in this
scenario is the sum of two opposing contributions.
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∆dG° = |∆dG°intr| - |∆G°switch|

(3.5)

The NL ground state remains thermodynamically favored as long as ∆dG° > 0. Ligandinduced distortion of the protein implies that conformers with open N-H sites are more
readily accessible than in the absence of L. Thus, ligand binding lowers ∆j values, resulting
in increased HDX rates throughout the protein (eq 3.4, Figure 3-7D).
The countless published examples17-20,22-32,36-37 of HDX rate reduction following
ligand binding demonstrate that Type 1 interactions represent by far the most common
scenario. Reports of Type 0 behavior are more scarce, although the use of HDX/MS for
verifying the absence of perturbations in antibody-drug conjugates is relevant in this
context.63 Type 2 behavior has been rarely, if ever, discussed. It remains unclear if (and
under what conditions) the occurrence of globally accelerated HDX kinetics after ligand
binding is a realistic scenario.

3.3.2. Oxygenation of Hemoglobin: Type 2 Binding.
Hb consists of two symmetric heterodimers, α1β1 and α2β2. The helical subunits within
each dimer interact closely with one another, whereas contacts across the α1β1/α2β2
interfaces are less extensive.64 Each subunit can bind O2 at its Fe(2+) heme. The cooperative
deoxy (T) → oxy (R) transition has been explored in great detail.54,65-68 Oxygenation causes a
~15° rotation of α1β1 relative to α2β2,65-66 thereby disrupting salt bridges between the
Lys40(α1/2) side chains and the β2/1 C-termini.67 Other α1β1/α2β2 contacts are weakened
as well. The structural distortion upon O2 binding carries a significant free energy penalty
∆G°switch,68-70 making Hb a likely candidate for a type 2 scenario.
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Figure 3-8: HDX kinetics of deoxy-Hb (open symbols) and oxy-Hb (filled symbols). The
two panels show data for the intact α (A) and β subunits (B) of the tetramer. Solid lines are
biexponential fits.

HDX/MS experiments on deoxy- and oxy-Hb were conducted in neutral solution.
Intact subunit measurements reveal that deuteration is greatly elevated for oxy-Hb compared
to deoxy-Hb. When averaged over the 2 h experimental time window, the deuteration
increase for α- and β-globin after oxygenation is about 15% and 20%, respectively (Figure 38). These data reveal that Hb indeed represents a type 2 binder. Our findings are consistent
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with earlier tritium labeling and HDX work.71-72 However, those studies did not discuss the
unusual nature of Hb-O2 interactions, which are different from the type 1 binding behavior
seen for most other proteins.17-20,22,36-37

Spatially-resolved HDX data were obtained using pepsin digestion and LC-MS. The
resulting peptide deuteration kinetics reflect the opening/closing dynamics exhibited by
individual Hb regions (Figures 3-3, 3-5). Deuteration percentages for t = 60 min were
mapped onto Hb crystal structures (Figure 3-9A, B). Segments in the interior of the tetramer
tend to be strongly protected (e.g., the center portions of helices G and H in both subunits,
Figure 3-9A, B, blue). Peripheral elements such as helices αA and βA exchange quite rapidly
(Figure 3-9B, red). The difference map of Figure 3-9C highlights the changes in deuteration
after oxygen binding. More extensive HDX takes place predominantly for elements that
contact the α1β1/α2β2 interfaces. Large deuteration increases are also seen for α87-98 and
β91-101 (Figure 3-5, Figure 3-9C, red). These two peptides comprise the proximal iron
ligands αHis87 and βHis91 which play a key role for transmitting movements of the iron
centers to the F helices.67 Thus, protein elements that directly participate in cooperative T →
R switching are those for which type 2 behavior is most pronounced.
The type 2 behavior of Hb reflects free energy partitioning upon oxygenation,
consistent with the model put forward in Figure 3-7D and eq 3.5. The intrinsic O2 binding
free energy is ∆dG°intr = 34 kJ mol-1 heme-1 when averaged over all four binding steps from
the deoxy-T to oxy-R.68 This intrinsic contribution arises from interactions of O2 with the
Fe(2+) center and hydrogen bonding with the distal His of helix E.73 A significant fraction of
this free energy (∆G°switch = 7 kJ mol-1 heme-1) is used up for T → R switching of the protein
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scaffold,68 thereby destabilizing the ground state structure and enhancing HDX kinetics as
dictated by eq 3.4. The resulting overall O2 binding affinity is ∆dG° = 34 – 7 = 27 kJ mol-1
heme-1 (eq 3.5).68
On the basis of these Hb data it is tempting to speculate that type 2 HDX might be
limited to cooperative multi-subunit systems. Interestingly, the observations discussed below
reveal that this is not the case.

3.3.3. Type 2 Oxygen Binding to Myoglobin.
Mb is a monomeric protein with a fold very similar to that of α- and β-globin.74 Mb-O2
interactions are virtually identical to those in Hb, involving a Fe(2+) heme and a distal His.54
However, protein structural changes upon Mb oxygenation are much less extensive than for
Hb.74 The average RMS displacement after O2 binding is only 0.2 Å for Mb, whereas that of
Hb is 1.1 Å.75 Due to the lack of subunit cooperativity Mb exhibits a hyperbolic O2 binding
profile, while the Hb oxygenation curve is sigmoidal.76 Thus, Mb represents an ideal model
system for scrutinizing possible linkages between binding cooperativity and type 2 behavior.
Intact protein data reveal that oxy-Mb shows more extensive HDX than deoxy-Mb (Figure 310). The deuteration enhancement is roughly one third of that seen for Hb (Figure 3-8).
Nonetheless, Figure 3-10 clearly demonstrates that O2 binding to Mb also represents a type 2
scenario. In other words, type 2 effects are not limited to proteins with multi-subunit
cooperativity.
Spatially-resolved HDX/MS measurements for Mb (Figure 3-2, 3-4) reveal extensive
structural dynamics in the N-terminus, and in the B/C/D loop region (Figure 3-11A, B). O2
binding significantly increases HDX levels in helices A and H (Figure 3-11C, red),
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resembling the behavior seen for Hb (Figure 3-9C). In addition, oxygenated Mb shows
strongly enhanced deuteration in helix E (Figure 3-11C, red) which participates in ligand
binding via the distal His64. This accelerated deuteration of helix E is somewhat different
from the behavior seen for Hb, where HDX enhancements are more pronounced on the
proximal side of the heme (helix βF, Figure 3-9C).
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Figure 3-9: Spatially-resolved deuteration pattern of (A) deoxy-Hb and (B) oxy-Hb for t =
60 min (PDB files 1HDA77 and 2QSS78). Complete time profiles are shown in Figure S3. (C)
HDX difference map averaged over the 2h experimental time window; red represents
segments that show most strongly elevated deuteration after O2 binding.
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The observation of type 2 behavior for Mb suggests that O2 binding to this protein is
also
associated with a free energy penalty ∆G°switch (eq 3.5). However, this ∆G°switch must be
smaller than the corresponding Hb value (less than 7 kJ mol-1),68-69 as implied by two
observations: (1) deuteration enhancements are less pronounced for Mb than for Hb (Figures
2.3, 2.5). (2) Although ∆dG°intr is virtually identical for the two proteins, the overall O2
binding affinity of Mb (∆dG° = 35 kJ mol-1)73 is larger than that of Hb (27 kJ mol-1 heme-1).68
In the case of Hb it is clear that ∆G°switch is dissipated via the disruption of protein-protein
contacts during T → R switching.68 In the case of Mb the fate of this free energy contribution
is not as clear. Our observations, as well as existing X-ray data74-75 are consistent with the
view that oxygenation-induced local changes on the heme build up conformational strain in
the protein. The Mb elements affected by this phenomenon display elevated deuteration rates
as a result of their increased pop values (red in Figure 3-11C).

3.3.4. Heme Binding to Apo-Myoglobin: A Type 1 Event.
Heme binding to apo-Mb results in significant stabilization of the protein. This transition has
been studied extensively,79-80 but we include it here for completeness as an example of a type
1 scenario. Heme makes numerous contacts within the hydrophobic binding pocket of the
protein, in addition to iron ligation by the proximal His93 in helix F.81

86

% Deuteration

75

apo-Mb

60

holo-Mb

+ O2
45

no O2

30

15
0

30

60

90

120

Time (min)

Figure 3-10: Intact protein HDX kinetics of holo-Mb in the oxy-state (filled symbols) and in
the deoxy-state (open symbols). Also included are data for the heme-free protein (apo-Mb,
red).

Heme-bound Mb exhibits dramatically lower deuteration values than the apo-state (Figure 310). Spatially resolved measurements (Figure 3-2) show that this stabilization affects all
regions of the protein (Figure 3-12A, B). The largest changes are seen around helix F (Figure
3-2) which adopts a well-defined structure only in the presence of heme.79 The type 1
character of the apo-Mb → holo-Mb transition is readily apparent from the HDX difference
map of Figure 3-12C which is completely blue. This has to be contrasted with the red
difference maps that apply to the oxygenation events discussed above (type 2 behavior,
Figure 3-9C, 3-11C).
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Figure 3-11: Spatially-resolved deuteration pattern of (A) deoxy-Mb and (B) oxy-Mb for t =
60 min (PDB files 2V1K82 and 1DWR83). Complete time profiles are shown in Figure S5.
(C) HDX difference map averaged over the 2h experimental time window; red represents
segments that show most strongly elevated deuteration after O2 binding.
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Figure 3-12: Spatially-resolved deuteration pattern of (A) apo-Mb and (B) oxy-Mb for t = 60
min. PDB file 1DWR83 was used for both panels because high resolution X-ray data for apoMb are not available. (C) Difference map averaged over the 2h experimental time window;
regions that show less extensive HDX in the presence of heme are highlighted in dark blue.
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3.4. Conclusions
This work demonstrates that protein-ligand interactions can result in a wide range of HDX
signatures. Binding can cause a global decrease of deuteration rates (type 1), or it may cause
accelerated deuteration (type 2). Both of these extremes are thermodynamically feasible
because the ensemble-averaged behavior of a protein is dominated by the ground state.
Binding is a spontaneous process as long as the free energy of NL is lower than that of N
(Figure 3-7). This criterion for spontaneity is irrespective of the excited state behavior,
because the cumulative Boltzmann occupancy of the corresponding conformers is low.33
Nonetheless, it is these sparsely populated open states that govern the HDX properties of the
protein according to eqs 3.1, 3.4. The largely unpredictable ligand-induced changes of ∆j
values translate into a range of possible deuteration scenarios (Figure 3-7). Type 1 and 2
scenarios are both compatible with either induced fit or conformational selection modes of
binding, whereas type 0 behavior may be more appropriately described as a lock-and-key
interaction.84-85
The observation of type 2 behavior is, perhaps, not so surprising in the case of Hb due
to the known interplay between ∆G°switch and ∆dG°intr which is a common feature of
cooperative multi-subunit proteins (Figure 3-7D).68 However, the observation that
oxygenation of Mb also represents a type 2 transition demonstrates that ligand-induced
deuteration enhancements are not limited to cooperative systems with multiple binding sites.
The cartoon representation of Figure 3-7 depicts just three conceivable scenarios that
might be encountered upon ligand binding. Other cases are certainly possible. For example,
data consistent with mixed type 1/0/2 scenarios have been reported.42,44-46 Also, individual
amide N-H groups do not have to remain associated with a certain type of opening event.
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Ligand-induced changes of the protein energy landscape may cause N-H sites to move within
the excited state manifold, e.g., from a low level in Figure 3-7A to a higher one in Figure 37B. Such differential free energy shifts provide an opportunity for binding site mapping,
keeping in mind that allosteric effects have to be considered for this type of experiment.1718,42

The prevalence of type 1 binding in the literature tends to foster the view that reduced
deuteration rates are a general hallmark of protein-ligand interactions.17-20,22-32,36-37 Our
findings demonstrate that it is easy to overlook biologically important interactions when
using screening approaches that exclusively focus on such type 1 scenarios. The observation
of type 2 behavior for two of the most “mundane” protein-ligand complexes (Hb-O2 and MbO2) suggests that non-canonical HDX scenarios may be more common than currently
thought. In any case, practitioners have to be aware that biological interactions in different
proteins may elicit very different types of HDX responses.
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Chapter 4. Activation of ClpP Protease by ADEP Antibiotics:
Insights from Hydrogen Exchange Mass Spectrometry

4.1. Introduction
The ability to degrade damaged or misfolded proteins is a prerequisite for maintaining a
healthy intracellular milieu.1 In eukaryotic cells the dominant non-lysosomal degradation
pathway proceeds via the ubiquitin-proteasome system.2 Prokaryotes3 and mitochondria4
mainly rely on members of the caseinolytic protease (Clp) family for ATP-dependent
degradation. ClpP is a member of this family that was initially discovered in Escherichia
coli,5 and that has become a paradigm for proteolytic degradation complexes in general.3,6-8
In ClpP fourteen identical subunits assemble into two stacked heptameric rings,
forming a 300 kDa barrel. The hydrolytically active sites are located inside a central chamber
that can be accessed via two axial pores.6-7,9-15 Each of the subunits consists of an N-terminal
region, a globular head domain, and a handle (Figure 4-1a-c).13,16 Contacts between the two
heptameric rings are mediated by intercalation of the handles from alternating subunits.16
ClpP by itself cannot hydrolyze large substrates because the axial pores are blocked by the
N-terminal regions of the seven subunits at both ends of the barrel (Fig. 4-1c).6-7,15,17-18
An active degradation complex that is capable of degrading full-length proteins is
formed when ClpP binds to AAA+ proteins such as ClpX or ClpA.3,6,19 These AAA+ proteins
are ATP-dependent unfoldases that form hexameric rings. They interact with ClpP
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,
Figure 4-1: X-ray structural data for E. coli ClpP. (a) ClpP monomer in the absence of
ADEP1. N-terminal region, head and handle regions are indicated. Residues 1-18 are
highlighted in red, the active site nucleophile S97 is shown in orange. (b) Equatorial and (c)
axial view of the ADEP1-free ClpP 14mer (pdb file 1YG6).9 (d) Single monomer, (e)
equatorial view, and (f) axial view of ClpP bound to ADEP1 (pdb file 3MT6).14 ADEP1
molecules are highlighted in magenta. Arrows in (e) highlight a slight dilation of the apical
(head) regions upon ADEP1 binding, as well as a subtle contraction in the equatorial plane.14

via insertion of hydrophobic loops into nonpolar clefts. These clefts are located between
adjacent ClpP subunits, surrounding the axial pores. The function of AAA+ proteins is to
recognize, bind, unfold, and translocate substrate proteins through the ClpP axial pores into
the degradation chamber.3,6,20-22 It has not been possible thus far to obtain X-ray structures of
intact ClpP/AAA+ complexes. Crystallization of these systems is complicated by the peculiar
symmetry mismatch, where heptameric ClpP rings are stacked against hexameric AAA+
rings.6-7,9 Thus, many functional aspects of these degradation machines remain unclear. Cryo104

electron microscopy (EM)22 revealed that binding to an AAA+ ring causes the corresponding
ClpP axial pore to open up, implying major structural changes of the ClpP N-terminal
regions. The open pore allows threading of unfolded substrates into the degradation chamber.
Unfortunately, the limited structural resolution of cryo-EM does not provide detailed
information on the nature of the pore opening transition.7 Another unresolved question
concerns the mechanism of product release, which may proceed via the ClpP axial pores,13,2324

or through openings that transiently form in the equatorial region.10,25-27
Acyldepsipeptides (ADEPs) are nonpolar antibacterial compounds.7 The parent

substance (ADEP1) has a lactone core derived from five amino acids, and an aliphatic C7H9
tail.15 ADEPs bind ClpP in the hydrophobic clefts that would normally interact with AAA+
proteins.7 Intriguingly, ADEP binding opens the ClpP axial pores (Figure 1d-f).6-7 This
transition allows ClpP to degrade a range of loosely folded proteins with high efficiency,
bypassing the requirement for AAA+ participation. The resulting uncontrolled proteolysis is
responsible for the antibiotic activity of ADEPs.28-29 Staphylococcus aureus and other Grampositive bacteria are susceptible to these compounds.30 Gram-negative organisms are largely
resistant because their outer membrane acts as protective barrier against ADEPs, and
possibly because of the presence of specific efflux pumps.31 Similar to the ADEP-bound
state, a constitutively active form of ClpP is obtained by deleting the first 14 N-terminal
residues.32
Deciphering the nature of ADEP-induced structural changes is complicated by the
fact that ClpP can crystallize in various conformations, pointing to a malleable structure that
is sensitive to crystal packing effects.7,9-10,26 This is particularly true for the N-terminal
regions which are key for gating the axial pores. Most of the available ClpP X-ray structures
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provide incomplete information for the first 18 residues, suggesting considerable disorder
and highly dynamic behavior. Nonetheless, it is clear that the N-terminal regions have a
propensity to form loops or hairpins, with two strands termed β-1 and β0.9-10,12-13,15,21,26-27
Recent X-ray studies led to two competing models for the ADEP-induced activation
of ClpP.7 According to one proposal,15 the closed-pore conformation has relatively structured
N-termini that are stabilized by hydrophobic clustering. Pore opening by ADEP was
attributed to switching of the termini to a more disordered state.15 This scenario has been
questioned,7 because the N-terminal regions in the open state of ref.15 appear to be influenced
by crystal packing. An alternative model14 envisions that ADEP binding triggers formation of
an “open collar”, consisting of β-1/β0 loops that are oriented parallel to the ClpP symmetry
axis (Figs. 4-1d-f).14 Both models agree that ADEP binding causes a slight equatorial
contraction, and a dilation of the axial regions (arrows in Fig. 4-1e).14-15
X-ray crystallography and cryo-EM provide static ground state structures that do not
directly reflect biomolecular dynamics in solution.7,33-34 For understanding protein behavior it
is essential to perform complementary investigations that probe dynamic features in a
physiologically relevant solvent environment. Relaxation dispersion NMR measurements
represent one promising avenue,25,35 but their application remains limited to very few
laboratories. Hydrogen/deuterium exchange (HDX) coupled with mass spectrometry (MS) is
a more accessible method.36-44 Protein regions that are disordered and/or highly dynamic
undergo rapid deuteration, whereas HDX in rigid segments is much slower. HDX rates
primarily reflect the stability of amide backbone H-bonds, although solvent accessibility also
plays a role.45 The deuteration behavior of individual segments can be monitored by
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subjecting the protein to peptic digestion after incubation in a D2O-containing environment.
This approach allows the tracking of time-dependent peptide mass shifts by MS.
Here, we employ HDX/MS for probing changes in the structure and dynamics of
ClpP upon activation by ADEP1. Ligand binding causes rigidification of the equatorial belt,
whereas the head regions undergo a slight destabilization. ADEP1-mediated switching to the
open-pore state causes surprisingly small changes in the HDX behavior of the N-terminal
regions. Our data suggest that gating of the axial pores is mainly based on alterations in the
packing of N-terminal nonpolar residues. Such a mechanism helps reconcile the two
competing proposals of the activation process.7,14-15 To the best of our knowledge, this work
represents the first HDX/MS study on the ADEP-mediated activation of ClpP.

4.2. Materials and Methods
4.2.1. Materials
HEPES and glycerol were from Sigma (St. Louis, MO, USA), and potassium chloride was
from Caledon (Ontario, Canada). D2O was from Cambridge Isotope Laboratories (Andover,
MA). Magnesium chloride was purchased from Merck (Darmstadt, Germany). All chemicals
were used as received. E. coli ClpP was overexpressed and purified from transformed E. coli
cells as described,46 and ADEP1 was purified from Streptomyces hawaiiensis fermentation
broth following established procedures.14
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4.2.2. Backbone

Amide

Hydrogen/Deuterium

Exchange

Mass

Spectrometry
The experiments started with 300 µM ClpP (on a monomer basis) in 10 mM magnesium
chloride, 100 mM KCl, 25 mM HEPES, and 10% glycerol (pH 7.5). ADEP1-bound samples
were prepared by adding 2 µL of ADEP1 in DMSO to 20 µL of ClpP solution, resulting in a
five-fold molar excess of ligand. These mixtures were pre-equilibrated for 24 h at 4 °C.
Deuteration was conducted at room temperature. HDX was initiated by addition of 9 volumes
of D2O containing labeling buffer which had the same salt and glycerol concentration as the
stock solution, for a final measured pH of 7.3. On the basis of previously measured
dissociation constants,47 the fraction of bound protein under labeling conditions was
estimated to be 99%. 30 µL aliquots were removed at various time points ranging from 1 to
360 min after initiating of labeling. These aliquots were quenched at pH 2.4 by addition of
HCl on ice, followed by flash freezing in liquid nitrogen and storage at -80 °C. For spatiallyresolved HDX/MS experiments, the aliquots were rapidly thawed to ~0 °C and manually
injected into a nanoACQUITY UPLC with HDX technology (Waters, Milford, MA)48 for
desalting and peptide separation within 15 min on an equilibrated reversed phase column
(BEH C18 1.7 µm, 1 mm × 100 mm) using a water/acetonitrile gradient in the presence of
0.1% formic acid at 40 µL min-1 . Online digestion was performed using a POROS pepsin
column (2.1 mm × 30 mm) from Life Technologies/Applied Biosystems (Carlsbad, CA) at
room temperature. The temperature for peptide trapping and reversed phase separation was
set to 1 °C. Blank (water) injections were performed in-between protein injections to
eliminate carryover.
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Mass analysis of peptides was performed on a Waters Synapt HDMS instrument with
source and desolvation temperatures of 80 and 300 °C, respectively, a cone voltage of 30 V,
and an electrospray voltage of 3 kV. The identity of each peptide was confirmed by tandem
MS based on the known ClpP sequence.9 Zero time point controls (m0) for the correction of
artifactual in-exchange were performed by first exposing ClpP to quenching buffer, followed
by brief D2O exposure, resulting in the same final solution composition as for all other
samples. Controls for fully exchanged ClpP (m100, for the correction of back exchange) were
prepared by incubating 30 µM ClpP in labeling solution at pH 2.0 for 24 h. Biolynx 4.1
(Waters) and HX-Express49 were employed to analyze the centroid mass of all peptides as a
function of labeling time. Deuteration levels were determined as

% Deuteration =

( m − m0 )
× 100%
(m100 − m0 )

(4.1)

Intact protein deuteration measurements were performed using a procedure similar to that
described above, but without using the integrated Waters HDX module. Protein separation
was achieved using a C4 column (Jupiter 5 µm Proteo, 50 mm × 1 mm; Phenomenex)
coupled to a UPLC pump at a flow rate of 100 µL min-1 without pepsin digestion. The
injection loop volume was 20 µL and the total amount of protein per injection was 600 pmol.
The injection syringe, column, injector and solvent delivery lines were kept at 0 °C in an ice
bath. All measurements were performed in triplicate. Error bars represent standard
deviations. Average deuteration differences for Figs. 4-6e, f were calculated as

average difference =

1
N

∑ (% Deuteration

ADEP 1

− % Deuteration free )

(4.2)

109

%Deuteration values were determined by using eq. 4.1. The sum extends over the N = 6 time
points that were measured for each peptide.

4.3. Results and Discussion
4.3.1. Global HDX Kinetics
As a first step to understand the interaction of ADEP1 with ClpP, deuteration measurements
were conducted at the level of intact subunits. Backbone amide HDX/MS data were recorded
for labeling times ranging from one minute to six hours (Figure 4-2). ADEP1-free ClpP
reaches a deuteration level of almost 60% at the end of the experimental time window.
ADEP1 binding causes a dramatic reduction in the extent of labeling, resulting in a
deuteration level that is ~20% lower after 6 h. This reduced deuterium uptake points to a
stabilization of the overall ClpP structure upon ligand binding, resulting in a state that (on
average) is less dynamic. Qualitatively similar ligand-induced stabilization effects have
previously been observed by HDX/MS for many other proteins.37,39,50-51
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Figure 4-2: Global ClpP HDX/MS kinetics recorded in the absence (open symbols) and
presence of ADEP1 (filled symbols). Lines represent biexponential fits.

4.3.2. Spatially-Resolved HDX/MS Measurements
A more detailed view of the ClpP conformational dynamics can be gained by analyzing the
HDX kinetics in a spatially-resolved fashion. Peptic digestion yielded 32 peptides with
signal-to-noise ratios that were adequate for deuteration measurements, with an overall
sequence coverage of 95% (Figure 4-3). Even without detailed analyses, it can be seen that
ADEP1 binding does not affect all ClpP regions in the same fashion (Figure 4-4). As
expected from the intact protein data, many peptides exhibit reduced deuteration levels in the
presence of ADEP1. Other peptides show virtually identical HDX behavior with and without
ADEP1. Surprisingly, there are also some segments that show higher deuteration levels after
ligand binding. These three scenarios are exemplified in Figure 4.4 for peptides 135-141, 5061 and 82-89.
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Figure 4-3: Sequence of E. coli ClpP.9 Solid lines represent peptides used for HDX/MS data
analyses, dashed lines represent redundant peptides. Secondary structure elements are
indicated. Selected hydrophobic residues are highlighted, matching the color scheme used in
Figs. 4-7b-d.

A summary of all peptide data is provided in the deuterium uptake curves of Figure
4.5. For the following discussion we will focus on a subset of peptides that cover the ClpP
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Figure 4-4: Unprocessed HDX/MS data for three ClpP peptic peptides recorded in the
absence (red solid lines) and in the presence (black dotted lines) of ADEP1 for three HDX
time points.

sequence in an almost contiguous fashion (solid lines in Figure 4-3). The availability of
redundant data is nonetheless important, because it provides an internal consistency control.
It is reassuring that peptides representing similar protein regions exhibit comparable kinetics
(e.g., 50-61/51-58, 61-71/62-71/62-75, 82-89/82-91, 142-152/143-149, 184-189/187-193 in
Fig. 4-5).
To facilitate the discussion of peptide-resolved HDX data, deuteration percentages
were mapped onto the crystal structure of ClpP in the absence (Figure 4-6a, b) and presence
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of ADEP1 (Figure 4-6c, d) for t = 60 min. The handle domain (α5 and β6’, residues 120 to
152) shows the most dramatic changes upon binding. In the absence of ADEP1 this region is
only
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Figure 4-5: HDX kinetics of peptides in free ClpP (open symbols) and after ADEP1 binding
(filled symbols). Residue numbers are indicated in each panel. Lines are biexponential fits.
Error bars represent standard deviations of triplicate measurements.
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marginally protected (β6’ is red and α5 is yellow, Figure 4-6a, b). ADEP1 binding causes a
major stabilization of the handle, particularly in the 135-152 range that covers much of α5
(green, Figure 4-6c, d). β6’ gets stabilized as well (orange, Figure 4-6c, d).
Ligand-induced changes in the head domain are more subtle. Many elements in this
region show high protection with and without ADEP1 (blue, Fig. 6a-d), such as 24-31 (β1),
43-48 (center of α2), and 103-119 (β5, parts of α4 and β6). As already noted, there are several
peptides in the head region that show higher HDX levels after ADEP1 binding.

Figure 4-6: Mapping of the of Figure 4-5 HDX/MS data to the X-ray structures of ClpP for t
= 60 min, shown for single ClpP subunits (top row), and for complete tetradecamers (bottom
row). Colors in (a) - (d) represent deuteration percentages, as defined in the legend. Gray
elements in (a) - (d) were not covered by peptide mapping. In (c) selected elements are
identified; note that only one of the two ADEP1 molecules that are in contact with the
subunit is shown. Panels (e), (f): HDX difference map. Colored regions correspond to
115

|average difference| > 5% (eq. 4.2). Segments that exhibit elevated deuteration after ADEP1
binding are depicted in red. Segments with reduced deuteration are shown in blue. All other
regions are depicted in gray.
This ligand-induced destabilization is particularly pronounced for 17-23 (α1) and 8291 (β3) which are part of the ADEP1 binding cleft (Figure 4-6c).14-15 The N-terminal region
(including β-1 and β0, red in Figs. 6a-d) is almost completely deuterated after 60 min,
regardless of ADEP1 binding.
An overview of the regions that undergo stabilization (blue) and destabilization (red)
after addition of ADEP1 is provided in Figure 4-6e, f. This representation uses a 5%
threshold, calculated as outlined in the Methods section. ADEP1-induced destabilization is
restricted to the head regions of the ClpP tetradecamer, whereas elements that are most
strongly stabilized by ADEP1 are found in the equatorial (handle) region. The resulting redblue-red pattern of Figure 4.6f bears a striking correlation with the ADEP1-induced domain
movements that have been inferred from X-ray structural data (arrows in Figure 4-1d).14, 15
Specifically, contraction of the equatorial belt is concomitant with enhanced HDX protection,
i.e., a more stable H-bonding network in this region. Conversely, dilation of the apical barrel
ends is accompanied by partial destabilization of the head domains.

4.3.3. Allosteric Nature of ADEP1 Binding
Ligand binding to a protein occurs spontaneously when the corresponding free energy
change, ∆bindG°, is negative. This thermodynamic stabilization upon binding lowers the
Boltzmann population of transiently populated excited conformers.52-53 The resulting
decrease in amide deuteration provides the basis of typical HDX ligand binding assays.37,39,50116

51

In some cases ligand-induced stabilization is most pronounced in the direct vicinity of the

binding site.37,54-57 Other systems show allosteric behavior, where the ligand affects regions
that are remote from the site of interaction.37,57-59
Our HDX data reveal that the interaction of ADEP1 with ClpP causes both local
changes and allosteric switching. Ligand binding in the apical region induces a major
rigidification of the equatorial region. This long-distance effect requires the transduction of
allosteric signals over ~30 Å, from the ADEP1 binding clefts to the handle elements α5 and
β6’. What makes the ClpP behavior quite unusual is the fact that ADEP1 destabilizes some
protein elements close to the binding site. At first sight, this effect seems to contradict the
tenet that binding always results in a thermodynamic stabilization.37,39,50-51 However, binding
equilibria are not governed by local effects, but by the overall free energy change. ∆bindG° is
the sum of many individual contributions, each of which can be stabilizing (< 0) or
destabilizing (> 0). Binding is a spontaneous process as long as the former outweigh the
latter. Evidently, this is the case for the system considered here.

4.3.4. Implications for Product Release
The highly dynamic behavior of the free ClpP equatorial region seen in our HDX
experiments (Figure 4-6a, b) is consistent with earlier NMR work.25 Along with other
observations,10,26-27 those NMR data were interpreted in favor of a model where free ClpP as
well as ClpP/AAA+ complexes release hydrolysis products via transiently formed equatorial
openings. The results seen here point in a different direction. The pronounced structural
stabilization in the handle regions (Figure 4-6c-f) makes it unlikely that ADEP1-bound ClpP
117

undergoes large opening/closing fluctuations that would be required for the formation of
transient equatorial cavities. Instead, our HDX data are consistent with a scenario where
product release occurs via the axial pores, as suggested previously.13,23-24 In principle, the
isotope exchange pattern of ADEP1-bound ClpP would also be compatible with the presence
of rigid equatorial openings that could participate in

Figure 4-7: (a) Initial 60 min HDX period for peptides 1-7 and 8-16. (b) Top view of the
axial pore region for free ClpP (1YG6).9 Key nonpolar residues (I, L, V, F, M) are
highlighted in color. The N-terminal region is shown only for the single subunit that adopts a
“down” conformation in the pdb file.9 Possible L2 and V3 positions (not resolved in the Xray data) are indicated by circles. (c) Approximate location of the “hydrophobic plug” that
will form by clustering of up to seven sets of L2/V3/M5/V6/I7 residues, when several Ntermini adopt similar “down” conformations. (d) Top view of the ADEP1-bound open state
(3MT6).14 Highlighted residues correspond to those in (b), (c). In addition, R22 and K25 are
shown in cyan (with δ-guanido and ε-amino groups omitted, as indicated in the text). Note
how the outside of the hydrophobic ring is stabilized by interactions with the ADEP1 alkyl
tails.
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product release. Currently existing X-ray structures do not show any evidence of large
equatorial openings.14-15 Given the highly malleable nature of ClpP, however, it is possible
that those crystal structures do not properly reflect all aspects of the handle domain behavior
in solution.

4.3.5. N-Terminal Changes During ADEP1-Mediated Pore Opening
The key N-terminal segments that are involved in gating of the axial pore are 1-7 (ALVP tail
and first three residues of β-1) and 8-16 (β-1, turn, β0). The nearby region 24-31 (β1) exhibits
very low deuteration levels with and without ADEP1, suggesting that β1 provides a rigid base
for gating movements of the N-terminus. Segment 17-23 (α1) serves as hinge between β1 and
the N-terminal region. Conformational switching of the latter may be facilitated by a
“softening” of α1, evident from its higher HDX levels after ADEP1 binding (red, Figure 46e).
Peptides 1-7 and 8-16 are among the most rapidly exchanging segments, both with
and without ADEP1 (Figure 4-5, Figure 4-7a). This observation is consistent with earlier
evidence of extensive N-terminal disorder.9-10,12-13,15,21,26-27,35 Yet, it is surprising that the
ADEP1-mediated pore opening transition is not accompanied by larger changes in the Nterminal HDX kinetics. Segment 8-16 shows almost no HDX protection, regardless of the
presence of ADEP1. The crystal structure of ADEP1-bound ClpP shows H-bonding between
β-1 and β0.14 However, our data imply that in solution these contacts are in rapid N-H⋅⋅⋅O=C
↔ N-H

O=C equilibrium, rendering the corresponding backbone hydrogens highly
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susceptible to exchange. We attribute stabilization of the β-1/β0 open collar conformation to
factors other than H-bonding (outlined below).
Compared to 8-16, peptide 1-7 shows more protection. Interestingly, HDX of 1-7 is
faster after ADEP1 binding (Figure 4-7a, 4-6e). Because H-bonding in the β-1/β0 region is
negligible (see previous paragraph), the alterations in the HDX behavior of 1-7 must be due
to solvent accessibility differences.45 In other words, segment 1-7 is less accessible in free
ClpP than after ADEP1 binding. Hydrophobic clustering is the dominant contributor to
solvent exclusion in proteins.60-61 Strikingly, segment 1-7 mainly consists of nonpolar
residues. These and other key nonpolar moieties have been highlighted in Figure 4-3 and
Figure 4-7 to facilitate the following discussion.
As pointed out elsewhere,7,15 a likely N-terminal structure for the closed-pore state of
free ClpP in solution is the “down“ conformation displayed by subunit C in pdb file 1YG6.9
In this conformation M5, V6, and I7 are in the vicinity of the pore center. The first four
residues are not resolved, but sequence dictates that L2 and V3 must be adjacent to M5, V6,
and I7 (Figure 4-7b). All five of these amino acids are nonpolar.62 Having multiple N-termini
adopt similar “down” orientations will place up to 7 × 5 = 35 nonpolar residues in direct
proximity to each other. We propose that clustering of these nonpolar moieties will result in a
“hydrophobic plug” that is stabilized by the surrounding nonpolar head residues (F17, L23,
L24, L48, F49, L50 from each subunit, Figure 4-7b). Figure 4-7c highlights the fact that such
a hydrophobic network will block the axial pores of free ClpP. In support of this scenario,
earlier studies already noted extensive hydrophobic contacts in the N-terminal region of free
ClpP.7,15 Also, mutations that lower the nonpolar character of the N-terminal region induce
partial opening of the pore, 35,63 consistent with destabilization of the hydrophobic plug.
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Why does ADEP1 binding open up the pore, and why does this transition increase the
HDX levels of peptide 1-7? X-ray structure 3MT614 shows that the ADEP1-bound open
collar state is devoid of an axial hydrophobic plug. Instead, the N-terminal residues L2, V3,
M5, V6, I7 are in contact with a nonpolar interaction network comprising F17, L23, L24,
L48, F49, L50 (Figure 4-7d). In the absence of firm H-bonds, we propose that this
hydrophobic clustering is the key stabilizing factor of the β-1/β0 loops in the open collar state.
Importantly, all seven ADEP1 molecules point their C7H9 alkyl tails towards the nonpolar
moieties that are located around the rim of the pore. Clearly, the open state is stabilized by
hydrophobic interactions between nonpolar residues and the ADEP1 alkyl tails (Figure 4-7d).
Formation of these interactions after ADEP1 binding seems to be a major factor for
triggering the transition to the open collar conformation. In addition, the opening event may
be facilitated by the slight dilation of the head domains that occurs as the ADEP1 molecules
wedge themselves into the binding clefts (arrows in Fig. 4-1e). We propose that the
accelerated HDX kinetics of peptide 1-7 in the open state reflect the enhanced solvent
accessibility of L2/V3/M5/V6/I7 after ADEP1-mediated disruption of the hydrophobic plug.
Interestingly, R22 and K25 participate in the closely packed nonpolar network of the
open pore conformation (Figure 4-7d, cyan). It might seem surprising to see K and R
participate in hydrophobic interactions, since both of these residues are charged. However,
the charges are located at the end of nonpolar chains (CαH-CH2-CH2-CH2-CH2-, and CαHCH2-CH2-CH2-, respectively), giving both K and R amphiphilic character. It is well known
that this architecture allows K and R to participate in hydrophobic packing, while at the same
time exposing their charged end groups to the solvent at the protein surface.53,64 Such a
scenario applies to the case of ADEP1-bound ClpP, as illustrated in Figure 4.7d (for clarity,
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the solvent-exposed guanido and amino groups of R22 and K25 have been omitted in the
Figure).

4.4. Conclusions
The interpretation of HDX measurements on protein-ligand systems is frequently guided by
the expectation that structural stabilization effects will be most pronounced in the vicinity of
the ligand, such that deuteration data can be used for binding site mapping.65 Indeed, there
are many proteins that behave according to this canonical scenario.37,54-57 Unfortunately, such
a simplistic “HDX footprinting” view is inadequate for systems that show allosteric
behavior,37,57 i.e., where the ligand affects structure and dynamics in regions that are remote
from the binding site.58-59 The ADEP1/ClpP system represents a case where a footprinting
interpretation of HDX patterns is inadequate. A simplistic analysis of the measured HDX
kinetics would erroneously suggest the equatorial region as ADEP1 binding site, because this
is where deuteration changes are most pronounced.
The HDX/MS data of this study complement previous work on the interaction of
ClpP with ADEP antibiotics. Our observations strongly suggest that the ADEP1-mediated
opening of the ClpP axial pores involves switching between two different modes of
hydrophobic packing. In free ClpP the clustering of nonpolar N-terminal residues yields a
hydrophobic plug that is centered around the symmetry axis of the barrel, blocking access to
the degradation chamber. ADEP binding dissolves this central plug by providing new
hydrophobic anchor points (the seven alkyl tails on the outside of the pore) that nonpolar
residues can bind to. By acting as hydrophobic nucleation sites, the ADEP1 molecules trigger
switching to a conformation that has all seven N-terminal regions sequestered away from the
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centerline of the barrel, thereby opening up the pore. Simply speaking, this gating mechanism
relies on the “hydrophobic pull” exerted by ADEP1, causing a radial movement of nonpolar
residues towards the outside.
Our view of the pore opening transition is consistent with X-ray structures of free9,15
and ADEP1-bound ClpP14 (Figure 4-7b-d). The scenario envisioned here helps resolve some
of the differences7 in the interpretation of earlier X-ray studies.14-15 This reconciliation
comprises (i) acknowledging the crucial role of hydrophobic clustering in the closed state as
noted in ref.15; and (ii) accepting that ADEP1 binding triggers the formation of an N-terminal
open collar as suggested in ref.14 (Figure 4-1f, 4-7d). Our data imply that this collar is
primarily stabilized by a network of hydrophobic moieties that comprises nonpolar side
chains as well as the seven ADEP1 alkyl tails. Given the HDX evidence for the highly
dynamic nature of the N-terminal regions, neither the hydrophobic plug in free ClpP, nor the
collar formed after ADEP1 binding should be envisioned as static entities.
In future work, it will be interesting to conduct HDX measurements on ClpP in
complex with AAA+ unfoldases. The C7H9 alkyl tail of ADEP1 mimics the first residue in
the IGF/L loops of ClpA and ClpX

14-15,28-31

These IGF/L loops are essential for the

association of AAA+ proteins with ClpP.66 Therefore, the model proposed here for opening
and stabilization of the ClpP axial pore by ADEP1 may be extendable to the ClpP
interactions with AAA+ proteins. In the absence of high-resolution X-ray data for
AAA+/ClpP complexes, HDX/MS might be able to prove or disprove such a proposal. Also,
future investigations should explore whether the interaction of ClpP with ADEPs shows
cooperative behavior, analogous to the T/R switching seen for hemoglobin and other
proteins.67-69
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Chapter 5. Noncovalent Binding of a Cyclic Peptide Inhibitor to
the Peptidyl-Prolyl Isomerase Pin1 Explored by Hydrogen
Exchange Mass Spectrometry

5.1. Introduction

Proteins owe their specific biological functions to unique three-dimensional structures. The
native fold of each protein is determined by numerous side chain interactions, as well as main
chain contacts, i.e., hydrogen bonds that stabilize α-helices and β-sheets.1 The partial double
bond character of backbone Cα(CO)-(NH)Cα groups favors a coplanar arrangement of the six
atoms adjacent to peptide linkages. Steric constraints dictate that the trans configuration is
greatly preferred.2 One exception to this rule are X-Pro bonds (where X can be any nonproline residue). The backbone-linked five-membered ring of Pro causes the cis and trans
isomers of the corresponding peptide bond to be relatively close in free energy.3-4 As a result,
the occurrence of cis X-Pro bonds in native proteins is quite high, on the order of 7%.5 The
cis-trans isomerization of X-Pro bonds is nonetheless a slow process that is associated with
an activation barrier on the order of 60 - 80 kJ mol-1.6-8
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Figure 5-1: (A) Crystal structure of human Pin1 (PDB 3TCZ).9 Selected active site residues
and secondary structure elements are highlighted. Hydrophobic residues are shown in blue,
cationic side chains are highlighted in orange, and the active site Cys113 is depicted in pink.
The WW domain is colored cyan. Not all of the Pin1 residues were resolved in the X-ray
data, causing the appearance of a discontinuous chain. (B) Representative NMR structure of
the Pin1 inhibitor [CRYPEVEIC] in the free (unbound) state.10 The square bracket notation is
used to indicate the cyclic nature of the peptide.

Peptidyl-prolyl isomerases (PPIases) catalyze the cis-trans conversion of X-Pro bonds.11 This
group of enzymes comprises a number of well-known members such as cyclophilins and
FK506-binding proteins.3 Of particular interest for the current work, Pin1 is a PPIase that
exhibits high specificity towards substrates where proline is preceded by phosphoserine or
phosphothreonine (pSer-Pro or pThr-Pro).3,12 Pin1 is involved in eukaryotic cell cycle
regulation,13 and as such it is a promising anticancer target.14-17 The C-terminal domain of the
largest subunit of RNA polymerase II is one of the primary Pin1 in vivo substrates,
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highlighting the involvement of Pin1 in transcription regulation.9,18 The phosphorylationdependent substrate specificity of Pin1 is consistent with its central role in
kinase/phosphatase mediated signaling pathways, many of which become deregulated in
cancer.19-20 In addition, Pin1 appears to be involved in disease states related to ageing, viral
infections, asthma, and Alzheimer’s disease.21-25
The 17.6 kDa amino acid sequence of Pin1 forms a N-terminal WW domain (residues
1-39) and a C-terminal PPIase domain (residues 45-163, Figure 5-1A).9,12 The former
consists of three antiparallel β strands (β1′ - β3′), whereas the latter has a mixed secondary
structure comprising strands β1 - β4 and helices α1 - α4. The relatively close contacts seen
between the two domains in X-ray structural data9,12 may not adequately reflect the
properties of Pin1 in solution where the WW and PPIase domains appear to be more
independent of one another.26 The reaction mechanism of Pin1 remains elusive, although
Cys113 clearly represents one of the key active site residues.27-28 Leu122, Met130, and
Phe134 form a hydrophobic binding pocket that accommodates the substrate proline, whereas
the cationic side chains of Lys63, Arg68, and Arg69 interact with the negatively charged
phosphate.12 While the catalytic function of Pin1 resides within the PPIase domain, the WW
domain may represent the initial site of substrate recognition.26,29
The role of Pin1 as a potential drug target has sparked the development of customdesigned inhibitors that compete for binding with the natural pSer/pThr-Pro substrates.9,30-37
Inhibitors carrying phosphate groups can act as substrate mimics; however, a problem with
this approach is the limited membrane permeability of phosphorylated compounds which
compromises their therapeutic potential.35 Hence, the identification of non-phosphorylated
Pin1 inhibitors remains an important goal. Peptide libraries are an interesting starting point
for Pin1 inhibitor screening. Unfortunately, the loss of conformational entropy upon complex
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formation tends to reduce the binding affinity of many peptides. A promising strategy to
overcome this problem is the use of cyclic peptides that experience a lower entropic penalty
upon noncovalent binding to the protein receptor.38 Liu et al.39 were the first to successfully
employ such a strategy for the development of Pin1 inhibitors. Similarly, Duncan et al.10
used phage display technology to identify the cyclic peptide [CRYPEVEIC] (square brackets
are used to denote the cyclic structure) as a highly selective ligand for the Pin1 PPIase
domain with a dissociation constant around 0.5 µM (Figure 5.1B). Cyclization of the peptide
was achieved by disulfide formation of the two terminal -SH groups. NMR spectroscopy was
successfully applied for elucidating the solution structure of free [CRYPEVEIC], but
unfortunately conformational information obtained for the protein-ligand complex was
extremely limited. Also, crystallization studies of the Pin1-[CRYPEVEIC] complex have
been unsuccessful to date.10
Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) is a widely used
approach for examining protein structure, dynamics, and interactions.40-51 Solvent-exposed
N-H sites in unstructured regions undergo deuteration with rate constants on the order of 1 s1 52

. Exchange at backbone sites that are involved in hydrogen bonds (e.g., in α-helices or β-

sheets) is much slower. HDX at these sites is mediated by structural fluctuations that lead to
the transient disruption of hydrogen bonds, coupled with backbone N-H exposure to the
solvent. Ligand binding usually stabilizes the protein, thereby reducing HDX rates. The
largest changes tend to occur in the vicinity of the binding site, although allosteric effects can
play a role as well.50-51 It is also possible that some segments exhibit higher HDX rates after
ligand binding, corresponding to local enhancements in protein dynamics.48,53-55
In the current work we use HDX/MS for exploring the response of Pin1 to
[CRYPEVEIC] binding. Especially in cases where X-ray crystallographic data are not
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available, HDX/MS can provide important insights into the nature of protein-ligand
interactions.50-51 Also, our aim was to identify highly mobile sequence regions in the Pin1[CRYPEVEIC] complex. The presence of such dynamic elements often prevents proteins
from crystallizing. It is likely that issues of this type were responsible for the lack of success
in previous crystallization attempts.10 It has been demonstrated for other proteins that
HDX/MS can guide the design of truncated protein variants with enhanced crystallization
propensity.56 Our results demonstrate that [CRYPEVEIC] binding causes marked deuteration
changes in the Pin1 PPIase domain. Many of these alterations reflect the occurrence of
ligand-induced stabilization, but interestingly there is also a long sequence stretch that
becomes more dynamic after [CRYPEVEIC] binding. These data yield novel information on
the nature of Pin1-ligand interactions, and they provide the foundation for future
crystallization trials on truncated protein constructs.

5.2. Experimental Section
5.2.1. Materials.
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was purchased from Sigma
(St. Louis, MO, USA), and D2O was from Cambridge Isotope Laboratories (Andover, MA).
All chemicals were used as received. The Arg14Ala variant of human Pin1 was
overexpressed in E. coli and isolated as described.10,57 [CRYPEVEIC] was purchased from
EZBiolab (Westfield, IN). The presence of the cyclic form was verified by ESI-MS, which
resulted in a mass of 1109.5 Da, 2 Da less than expected for the linear amino acid sequence.
This mass difference corresponds to the loss of two hydrogens as the terminal cysteine
residues get linked via a -S-S- bond.
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5.2.2. Backbone

Amide

Hydrogen/Deuterium

Exchange

Mass

Spectrometry.
The experiments started with 100 µM Pin1 in 10 mM HEPES/100 mM NaCl (pH 7.7).
[CRYPEVEIC]-bound samples were prepared by adding 2 µL of 25 mM [CRYPEVEIC] in
water to 13 µL of Pin1 solution, resulting in a five-fold molar excess of ligand. These
mixtures were pre-equilibrated for 24 h at 4 °C. Deuteration was conducted at room
temperature. HDX was initiated by addition of 9 volumes of D2O-based labeling buffer
which had the same salt concentration as the stock solution, for a final measured pH of 7.7
and a protein concentration of 10 µM. For Kd ≈ 0.5 µM10 the fraction of bound protein under
HDX conditions was estimated to be 99%. 30 µL aliquots were removed at various time
points ranging from 1 to 360 min after initiating of labeling. These aliquots were quenched at
pH 2.4 by addition of HCl on ice, followed by flash freezing in liquid nitrogen and storage at
-80 °C. For spatially-resolved HDX/MS experiments, the aliquots were rapidly thawed to ~0
°C and manually injected into a nanoACQUITY UPLC with HDX technology (Waters,
Milford, MA)58 for desalting and peptide separation within 15 min on an equilibrated
reversed phase column (BEH C18 1.7 µm, 1 mm × 100 mm) using a water/acetonitrile
gradient in the presence of 0.1% formic acid at 35 µL min-1 . Online digestion was performed
on a POROS pepsin column (2.1 mm × 30 mm) from Life Technologies/Applied Biosystems
(Carlsbad, CA) at room temperature. The temperature for peptide trapping and reversed
phase separation was set to 1 °C. Blank (water) injections in-between protein injections
ensured the absence of sample carryover.
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Mass analysis of peptides was performed on a Waters Synapt HDMS instrument with
source and desolvation temperatures of 80 and 300 °C, respectively, a cone voltage of 30 V,
and an electrospray voltage of 2.8 kV. The identity of each peptide was confirmed by tandem
MS based on the known Pin1 sequence. Zero time point controls (m0) for the correction of inexchange were performed by exposing Pin 1 to quenching buffer, followed by D2O exposure,
resulting in the same final solution composition as for all other samples. Controls for fully
exchanged Pin1 (m100, for the correction of back exchange) were prepared by incubating 30
µM Pin 1 in labeling solution at pH 2.0 for 6 days. Biolynx 4.1 (Waters) and HX-Express59

were employed to analyze the centroid mass of all peptides as a function of labeling time.
Deuteration levels (%D) were determined as

%D=

( m − m0 )
× 100%
( m100 − m0 )

(5.1)

Average deuteration differences for Figs. 5.6 were calculated as

average difference =

1
N

∑ (% D

[ CRYPEVEIC ]

− % D free )

(5.2)

The sum extends over the N = 6 time points that were measured for each peptide. All
measurements were performed in triplicate. Error bars represent standard deviations. The
Pin1 sequence numbering used here for reporting our data is consistent with that commonly
used in the literature9, where the active site cysteine corresponds to position 113. Hence, the
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N-terminal residue is referred to as Lys6 (instead of Lys1). This implies that after the HDX
analysis all residue numbers had to be increased by five.

5.3. Results and Discussion
Peptic digestion of Pin1 under HDX conditions resulted in 28 identifiable peptides,
corresponding to a sequence coverage of 80 % (Figure 5-2). Even without any data
processing, it is evident that the presence of [CRYPEVEIC] has noticeable effects on the
structural dynamics of

Figure 5-2: Sequence and secondary structure elements of Pin1, with the conventionally
used residue numbering.9 Solid lines represent peptides used for the graphic representation of
deuteration levels in Figs. 5-5, 5-6. Dashed lines represent redundant peptides.
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Pin1. The peptide behavior can be categorized into three groups as illustrated in Figure 5-3.
Some peptides exhibited only very minor differences in their deuteration kinetics upon
addition of the ligand (e.g., residues 140-160, Figure 5-3A). Others showed significantly
reduced deuteration in the presence of [CRYPEVEIC], indicating the occurrence of ligandinduced rigidification (e.g., 139-151, Figure 5-3B). Interestingly, there were also some
segments where deuteration was enhanced after [CRYPEVEIC] binding, such as 74-86
(Figure 5-3C).
A comprehensive overview of the spatially-resolved HDX kinetics is provided in
Figure 5-4. These data illustrate that the deuteration behavior of the various Pin1 segments is
highly dependent on the position within the sequence.

ESI-MS Intensity

140-160

139-151
Pin1 alone
With Ligand

A

740

742

74-86

B

C

708

710

712

402

403

m/z

Figure 5-3: Unprocessed HDX/MS data for three Pin 1 peptic peptides recorded in the
absence (black solid lines) and in the presence (red dotted lines) of [CRYPEVEIC] for a
deuteration time of t = 360 min. The sequence range of the three peptides is indicated along
the top.
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Peptides towards the N-terminus display very rapid deuterium uptake, indicating that
the corresponding protein regions are highly dynamic, with backbone N-H groups that are
either unprotected or engaged in hydrogen bonds that are only marginally stable. In contrast,
C-terminal segments exhibit a much higher protection against deuteration, reflecting the
presence of stable secondary structure.
To facilitate a discussion of the Pin1 response to ligand binding, HDX data for a
labeling time of 1 h were mapped to the X-ray structure of the protein (Figure 5-5). The Nterminal WW domain is displayed in red, signifying its near-complete deuteration both in the
presence and in the absence of [CRYPEVEIC]. The extremely dynamic nature of this domain
is somewhat unexpected, considering that isolated Pin1 WW constructs have served as model
systems in folding experiments where they were treated as independently stable moieties.60
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Figure 5-4: Normalized deuteration kinetics of Pin1 peptic peptides (%D, determined on the
basis of eq. 5.1). Each panel shows data recorded in the absence of ligand (open circles) and
in the presence of [CRYPEVEIC] (filled symbols). Lines are biexponential fits. Error bars
represent standard deviations of triplicate measurements.

However, crystallization efforts of the isolated WW domain were unsuccessful for many
years. Only very recently has it been possible to overcome this problem using a racemic
mixture in the presence of small-molecule additives.61 These crystallization difficulties have
been attributed to the highly dynamic nature of the Pin1 WW domain.61 Our HDX/MS data
are in line with these findings, and they furthermore reveal that the WW domain remains
highly dynamic even in the context of intact Pin1. The conformational flexibility of the WW
domain is also consistent with the fact that all existing Pin1 X-rays structures have a number
of unresolved residues in the N143

Figure 5-5: Mapping of the HDX data from Figure 5.4 to the crystal structure of Pin1 for a
deuteration time of t = 60 min in the absence of ligand (A) and in the presence of
[CRYPEVEIC]. Colors represent deuteration percentages as indicated in the legend. Gray
color represents regions that were not covered during peptide mapping.

Terminal region.9,12,62 In contrast to the WW domain, the PPIase domain of Pin1 showed
deuteration kinetics that were much more distinct, consistent with the presence of welldeveloped secondary structure. Most of the PPIase domain elements displayed HDX levels
ranging between 40 and 80% after one hour of deuteration (Figure 5-5, yellow and orange).
The most protected element is β4 which is deeply buried (Figure 5-5, blue).
Changes in the deuteration pattern of Pin1 after [CRYPEVEIC] binding are displayed
in Figure 5-6. Regions that underwent significant alterations upon addition of the ligand are
highlighted in color, whereas all other segments are shown in gray. The color pattern of
Figure 5-6 again highlights that ligand-induced changes are confined to the PPIase domain,
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whereas the WW domain does not interact with [CRYPEVEIC]. This finding is consistent
with recent chemical shift perturbation results.10

Figure 5-6: Deuteration difference map of Pin1 before and after [CRYPEVEIC] binding,
calculated on the basis of eq. 5.2. Segments with reduced deuteration after ligand binding are
represented in blue, while those with enhanced deuteration are shown in red, as indicated in
the color legend.

Pronounced stabilization is seen for β2, α3, and α4 (Fig. 5-6, blue) which are known to be
involved in substrate binding. β2 and α4 carry the residues that form the hydrophobic Pro
binding pocket, whereas α3 comprises the active site Cys113 (cf. Figure 5-1A).10,12
Intriguingly, the sequence stretch covering residues 61 to 86 displayed elevated deuteration
in the presence of [CRYPEVEIC], implying the occurrence of enhanced conformational
dynamics after ligand binding (Figure 5-6, red). Most of these residues fold into a doublelooped structure that connects β1 and α1. X-ray data9 show that at least five N-H sites in this
region form strong backbone hydrogen bonds. The destabilized region identified here
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comprises the basic residues Lys63, Arg68, and Arg69 which bind the negatively charged
phosphate of natural pSer-Pro or pThr-Pro substrates.12 NMR shift perturbation data
suggested that neither Lys63 nor Arg68 interact strongly with [CRYPEVEIC].10 While the
data of the current work cannot pinpoint individual residues, our HDX/MS results clearly
demonstrate that residues in the 61-86 range do respond to the presence of the inhibitor. The
observation of enhanced deuteration strongly suggests that these interactions are unfavorable.
In other words, [CRYPEVEIC] binding to Pin1 distorts the 61-86 range in a way that
weakens hydrogen bonding in this segment. Assuming that P4 of [CRYPEVEIC] occupies its
canonical hydrophobic pocket (Figure 5-1A, blue)12, it seems likely that steric clashes of
Pin1 with either Y3 or E5 are responsible for destabilizing the 61-86 segment. One
possibility is that the E5 carboxylate interacts with the positively charged side chains of
Lys63, Arg68, or Arg69 by acting as a poor phosphate mimic. In any case, the enhanced
deuterium uptake seen here for the “red” elements of Figure 5-6 originates from a partially
distorted Pin1 structure that arises as the protein accommodates the inhibitor. The occurrence
of ligand-induced destabilization in selected protein regions has been reported in a few
previous studies on other systems.48,53-55 In general, however, this phenomenon is uncommon
because ligand binding is normally dominated by an overall protein stabilization that
manifests itself as a reduction in deuteration levels.46-47 Even for the Pin1-[CRYPEVEIC]
interaction studied here such stabilizing effects are prevalent, seen from the many “blue”
sequence regions in Figure 5-6.
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5.4. Conclusions
The cyclic peptide [CRYPEVEIC] was recently identified as a potent Pin1 inhibitor,
demonstrating that the presence of a phosphate group is not an absolute prerequisite for Pin1
binding.10 In other words, the protein will also interact with compounds that do not possess
the pSer-Pro or pThr-Pro motif found in natural substrates. [CRYPEVEIC] represents a
promising lead compound for membrane-permeable anticancer agents. Efforts to refine the
architecture of [CRYPEVEIC]-like compounds would greatly benefit from the availability of
high resolution X-ray structures that reveal the exact mode of inhibitor binding to Pin1. The
lack of success in generating suitable crystals of [CRYPEVEIC]-bound Pin1 thus represents
a major impediment. One approach to deal with this type of problem is the use of “disorderdepleted” protein constructs that may be more amenable to crystallization. HDX/MS has
previously been employed for identifying flexible regions that may interfere with crystal
nucleation and growth.56 The HDX/MS experiments of the current work identify the loop
region of residues 61-86 as having an elevated degree of disorder after [CRYPEVEIC]
binding. Protein constructs with truncations in this region may therefore be more amenable to
the formation of high quality crystals than full-length Pin1. Crystallization trials on such
constructs are currently underway, and the results of these efforts will be reported elsewhere.
From a more general perspective, [CRYPEVEIC] binding to Pin1 illustrates that
ligand interactions can be associated with a complex pattern of stabilizing and destabilizing
factors. In HDX/MS this leads to scenarios where some regions display lower deuteration
whereas others are more deuterated in the presence of ligand (blue and red, respectively, in
Fig. 5-6). There is a small but growing number of protein-ligand systems for which similar
effects have been reported previously.48,53-55 Recent work has demonstrated that it is even
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feasible for ligand binding to accelerate HDX kinetics in a global fashion.63 In any case, the
observation of these and other phenomena illustrates the capability of HDX/MS to probe
intricate details of biomolecular structure and interactions.

148

5.5. References
1.

Anfinsen, C. B., Principles that Govern the Folding of Protein Chains. Science 1973,

181, 223-230.
2.

Corey, R. B.; Pauling, L., Fundamental Dimensions of Polypeptide Chains. Proc. R.

Soc. London B 1953, 141 (902), 10-20.
3.

Lu, P. K.; Finn, G.; Lee, H. T.; Nicholson, L. K., Prolyl cis-trans isomerization as a

molecular timer. Nat. Chem. Biol. 2007, 3, 619-629.
4.

Zimmerman, S. S.; Scheraga, H. A., Stability of cis, trans, and nonplanar peptide

groups. Macromolecules 1976, 9 (3), 408-416.
5.

Stewart, D. E.; Sarkar, A.; Wampler, J. E., Occurence and Role of cis Peptide-Bonds

in Protein Structures. J. Mol. Biol. 1990, 214 (1), 253-260.
6.

Grathwohl, C.; Wuthrich, K., NMR-Studies of the Rates of Proline Cis-Trans

Isomerization in Oligopeptides. Biopolymers 1981, 20 (12), 2623-2633.
7.

Brandts, J. F.; Halvorson, H. R.; Brennan, M., Consideration of the Possibility That

the Slow Step in Protein Denaturation Reactions Is Due to Cis-Trans Isomerism of Proline
Residues. Biochemistry 1975, 22, 4953-4963.
8.

Houry, W. A.; Scheraga, H. A., Nature of the Unfolded State of Ribonuclease A:

Effect of Cis-Trans X-Pro Peptide Bond Isomerisation. Biochemistry 1996, 35, 11719-11733.
9.

Zhang, M. M.; Wang, X. J.; Chen, X.; Bowman, M. E.; Luo, Y. H.; Noel, J. P.;

Ellington, A. D.; Etzkorn, F. A.; Zhang, Y., Structural and Kinetic Analysis of Prolylisomerization/Phosphorylation Cross-Talk in the CTD Code. ACS Chem. Biol. 2012, 7 (8),
1462-1470.
149

10.

Duncan, K. E.; Dempsey, B. R.; Killip, L. E.; Adams, J.; Bailey, M. L.; Lajoie, G. A.;

Litchfield, D. W.; Brandl, C. J.; Shaw, G. S.; Shilton, B. H., Discovery and Characterization
of a Nonphosphorylated Cyclic Peptide Inhibitor of the Peptidylprolyl Isomerase, Pin1. J.
Med. Chem. 2011, 54 (11), 3854-3865.
11.

Schiene-Fischer, C.; Aumuller, T.; Fisher, G., Peptide Bond cis/trans Isomerases: A

Biocatalysis Perspective of Conformational Dynamics in Proteins. In Molecular Chaperones,
Jackson, S., Ed. Springer-Verlag Berlin: Berlin, 2013; Vol. 328, pp 35-67.
12.

Ranganathan, R.; Lu, K. P.; Hunter, T.; Noel, J. P., Structural and functional analysis

of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent.
Cell 1997, 89 (6), 875-886.
13.

Lu, K. P.; Hanes, S. D.; Hunter, T., A human peptidyl-prolyl isomerase essential for

regulation of mitosis. Nature 1996, 380, 544-547.
14.

Uchida, T.; Takamiya, M.; Takahashi, M.; Miyashita, H.; Ikeda, H.; Terada, T.;

Matsuo, Y.; Shirouzu, M.; Yokoyama, S.; Fujimori, F.; Hunter, T., Pin1 and Par14 Peptidyl
Prolyl Isomerase Inhibitors Block Cell Proliferation. Chem. Biol. 2003, 10, 15-24.
15.

Rustighi, A.; Zannini, A.; Tiberi, L.; Sommaggio, R.; Piazza, S.; Sorrentino, G.;

Nuzzo, S.; Tuscano, A.; Eterno, V.; Benvenuti, F.; Santarpia, L.; Aifantis, I.; Rosato, A.;
Bicciato, S.; Zambelli, A.; Sal, G. D., Prolyl-isomerase Pin1 controls normal and cancer stem
cells of the breast. EMBO J. 2014, 6, 99-119.
16.

Lu, K. P., Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and

therapeutics. Cancer Cell 2003, 4 (3), 175-180.
17.

Wang, X. D. J.; Etzkorn, F. A., Peptidyl-prolyl isomerase inhibitors. Biopolymers

2006, 84 (2), 125-146.

150

18.

Xu, Y. X.; Hirose, Y.; Zhou, X. Z.; Lu, K. P.; Manley, J. L., Pin1 modulates the

structure and function of human RNA polymerase II. Genes Dev. 2003, 17 (22), 2765-2776.
19.

Blume-Jensen, P.; Hunter, T., Oncogenic kinase signalling. Nature 2001, 411, 355-

365.
20.

St-Denis, N. A.; Litchfield, D. W., From birth to death: The role of protein kinase

CK2 in the regulation of cell proliferation and survival. Cell. Mol. Life Sci. 2009, 66 (11-12),
1817-1829.
21.

Lee, T.-H.; Pastorino, L.; Lu, K. P., Peptidyl-prolyl cis–trans isomerase Pin1 in

ageing, cancer and Alzheimer disease. Expert Rev. Mol. Med. 2011, 13, 1-26.
22.

Guito, J.; Gavina, A.; Palmeri, D.; Lukac, D. M., The Cellular Peptidyl-Prolyl

cis/trans Isomerase Pin1 Regulates Reactivation of Kaposi’s Sarcoma-Associated
Herpesvirus from Latency. J. Virol. 2014, 88, 647.
23.

Lonati, E.; Brambilla, A.; Milani, C.; Masserini, M.; Palestini, P.; BulbarellI, A.,

Pin1, a new player in the fate of HIF-1α degradation: an hypothetical mechanism inside
vascular damage as Alzheimer’s disease risk factor. Front. Cell. Neurosci. 2014, 8, 1-11.
24.

Wang, J.-Z.; Zhu, W.-D.; Xu, Z.-X.; Du, W.-T.; Zhang, H.-Y.; Sun, X.-W.; Wang,

X.-H., Pin1, endothelial nitric oxide synthase, and amyloid-b form a feedback signaling loop
involved in the pathogenesis of Alzheimer’s disease, hypertension, and cerebral amyloid
angiopathy. J. Med. Hypotheses 2014, 82, 145-150.
25.

Inoue, K. I.; Takano, H.; Kumagai, Y., Pin 1 blockade in asthma by naphthoquinone?

J. Allergy Clin. Immunol. 2008, 121 (4), 1064-1064.

151

26.

Jacobs, D. M.; Saxena, K.; Vogtherr, M.; Bernado, P.; Pons, M.; Fiebig, K. M.,

Peptide binding induces large scale changes in inter-domain mobility in human Pin1. J. Biol.
Chem. 2003, 278 (28), 26174-26182.
27.

Bailey, M. L.; Shilton, B.; Brandl, C. J.; Litchfield, D. W., The Dual Histidine Motif

in the Active Site of Pin1 Has a Structural Rather than Catalytic Role. Biochem 2008, 47,
11481-11489.
28.

Behrsin, C. D.; Bailey, M. L.; Bateman, K. S.; Hamilton, K. S.; Wahl, L. M.; Brandl,

C. J.; Shilton, B. H.; Litchfield, D. W., Functionally important residues in the peptidyl-prolyl
isomerase Pin1 revealed by unigenic evolution. J. Mol. Biol. 2007, 365 (4), 1143-1162.
29.

Lu, P. J.; Zhou, X. Z.; Shen, M.; Lu, K. P., Function of WW Domains as

Phosphoserine- or Phosphothreonine-Binding Modules. Science 1999, 283, 1325-1328.
30.

Bayer, E.; Thutewohl, M.; Christner, C.; Tradler, T.; Osterkamp, F.; Waldmann, H.;

Bayer, P., Identification of hPin1 inhibitors that induce apoptosis in a mammalian Ras
transformed cell line. Chem. Commun. 2005, 516-518.
31.

Daum, S.; Erdmann, F.; Fischer, G.; Feaux de Lacroix, B.; Hessamian-Alinejad, A.;

Houben, S.; Frank, W.; Braun, M., Aryl Indanyl Ketones: Efficient Inhibitors of the Human
Peptidyl Prolyl cis/trans Isomerase Pin1 Angew. Chem. 2006, 45, 7454-7458.
32.

Braun, M.; Hessamian-Alinejad, A.; Féaux de Lacroix, B.; Alvarez, B. H.; Fischer,

G., Novel Spiroannulated 3-Benzofuranones. Synthesis and Inhibition of the Human Peptidyl
Prolyl cis/trans Isomerase Pin1. Molecules 2008, 13, 995-1003.
33.

Guo, C.; Hou, X.; Dong, L.; Dagostino, E.; Greasley, S.; Ferre, R.; Marakovits, J.;

Johnson, M. C.; Matthews, D.; Mroczkowski, B.; Parge, H.; VanArsdale, T.; Popoff, I.;
Piraino, J.; Margosiak, S.; Thomson, J.; Los, G.; Murray, B. W., Structure-based design of
novel human Pin1 inhibitors (I). Bioorg. Med. Chem. 2009, 19, 5613-5616.
152

34.

Tatara, Y.; Lin, Y.-C.; Bamba, Y.; Mori, T.; Uchida, T., Dipentamethylene thiuram

monosulfide is a novel inhibitor of Pin1. biochem. Biophys. Res. Comm. 2009, 384, 394-398.
35.

Dong, L.; Marakovits, J.; Hou, X.; Guo, C.; Greasley, S.; Dagostino, E.; Ferre, R.;

Johnson, M. C.; Kraynov, E.; Thomson, J.; Pathak, V.; Murray, B. W., Structure-based
design of novel human Pin1 inhibitors (II). Bioorg. Med. Chem. 2010, 20, 2210-2214.
36.

Potter, A.; Oldfield, V.; Nunns, C.; Fromont, C.; Ray, S.; Northfield, C. J.; Bryant, C.

J.; Scrace, S. F.; Robinson, D.; Matossova, N.; Baker, L.; Dokurno, P.; Surgenor, A. E.;
Davis, B.; Richardson, C. M.; Murray, J. B.; Moore, J. D., Discovery of cell-active phenylimidazole Pin1 inhibitors by structure-guided fragment evolution. Bioorg. Med. Chem. 2010,
20, 6483-9488.
37.

Aluise, C. D.; Rose, K.; Boiani, M.; Reyzer, M. L.; Manna, J. D.; Tallman, K.; Porter,

N. A.; Marnett, L. J., Peptidyl-prolyl cis/trans-Isomerase A1 (Pin1) Is a Target for
Modification by Lipid Electrophiles. Chem. Res. Toxicol. 2013, 26 (2), 270-279.
38.

Katz, B. A.; Johnson, C.; Cass, R. T., Structure-based design of high affinity

streptavidin binding cyclic peptide ligands containing thioether crosslinks. J. Am. Chem. Soc.
1995, 117 (33), 8541-8547.

39.

Liu, T.; Liu, Y.; Kao, H.-Y.; Pei, D., Membrane Permeable Cyclic Peptidyl Inhibitors

against Human Peptidylprolyl Isomerase Pin1. J. Med. Chem. 2010, 53, 2494-2501.
40.

Konermann, L.; Pan, J.; Liu, Y., Hydrogen Exchange Mass Spectrometry for

Studying Protein Structure and Dynamics. Chem. Soc. Rev. 2011, 40, 1224-1234.
41.

Kaltashov, I. A.; Bobst, C. E.; Abzalimov, R. R., Mass spectrometry-based methods

to study protein architecture and dynamics. Protein Sci. 2013, 22 (5), 530-544.

153

42.

Iacob, R. E.; Engen, J. R., Hydrogen Exchange Mass Spectrometry: Are We Out of

the Quicksand? J. Am. Soc. Mass Spectrom. 2012, 23, 1003-1010.
43.

Englander, S. W., Hydrogen exchange and mass spectrometry: A historical

perspective. J. Am. Soc. Mass Spectrom. 2006, 17 (11), 1481-1489.
44.

Rob, T.; Liuni, P.; Gill, P. K.; Zhu, S. L.; Balachandran, N.; Berti, P. J.; Wilson, D. J.,

Measuring Dynamics in Weakly Structured Regions of Proteins Using Microfluidics-Enabled
Subsecond H/D Exchange Mass Spectrometry. Anal. Chem. 2012, 84, 3771-3779.
45.

Johnson, R. S.; Walsh, K. A., Mass spectrometric measurement of protein amide

hydrogen exchange rates of apo- and holo-myoglobin. Protein Sci. 1994, 3, 2411-2418.
46.

Powell, K. D.; Ghaemmaghami, S.; Wang, M. Z.; Ma, L.; Oas, T. G.; Fitzgerald, M.

C., A General Mass Spectrometry-Based Assay for the Quantitation of Protein-Ligand
Binding Interactions in Solution. J. Am. Chem. Soc. 2002, 124, 10256-10257.
47.

Zhu, M. M.; Rempel, D. L.; Du, Z. H.; Gross, M. L., Quantification of protein-ligand

interactions by mass spectrometry, titration, and H/D exchange: PLIMSTEX. J. Am. Chem.
Soc. 2003, 125 (18), 5252-5253.
48.

Asuru, A. P.; An, M.; Busenlehner, L. S., Dissection of Porphyrin-Induced

Conformational Dynamics in the Heme Biosynthesis Enzyme Ferrochelatase. Biochemistry
2012, 51 (36), 7116-7127.

49.

Keppel, T. R.; Howard, B. A.; Weis, D. D., Mapping Unstructured Regions and

Synergistic Folding in Intrinsically Disordered Proteins with Amide H/D Exchange Mass
Spectrometry. Biochemistry 2011, 50 (40), 8722-8732.

154

50.

Percy, A. J.; Rey, M.; Burns, K. M.; Schriemer, D. C., Probing protein interactions

with hydrogen/deuterium exchange and mass spectrometry-A review. Anal. Chim. Acta 2012,
721, 7-21.
51.

Chalmers, M. J.; Busby, S. A.; Pascal, B. D.; West, G. M.; Griffin, P. R., Differential

hydrogen/deuterium exchange mass spectrometry analysis of protein-Ligand interactions.
Exp. Rev. Proteomics 2011, 8, 43-59.
52.

Bai, Y.; Milne, J. S.; Mayne, L.; Englander, S. W., Primary Structure Effects on

Peptide Group Hydrogen Exchange. Proteins: Struct., Funct., Genet. 1993, 17, 75-86.
53.

Sowole, M. A.; Alexopoulos, J. A.; Cheng, Y.-Q.; Ortega, J.; Konermann, L.,

Activation of ClpP Protease by ADEP Antibiotics: Insights from Hydrogen Exchange Mass
Spectrometry. J. Mol. Biol. 2013, 425 (22), 4508-4519.
54.

Burke, J. E.; Babakhani, A.; Gorfe, A. A.; Kokotos, G.; Li, S.; Woods, V. L.;

McCammon, J. A.; Dennis, E. A., Location of Inhibitors Bound to Group IVA Phospholipase
A(2) Determined by Molecular Dynamics and Deuterium Exchange Mass Spectrometry. J.
Am. Chem. Soc. 2009, 131 (23), 8083-8091.
55.

Bobst, C. E.; Zhang, M.; Kaltashov, I. A., Existence of a Noncanonical State of Iron-

Bound Transferrin at Endosomal pH Revealed by Hydrogen Exchange and Mass
Spectrometry. J. Mol. Biol. 2009, 388 (5), 954-967.
56.

Pantazatos, D.; Kim, J. S.; Klock, H. E.; Stevens, R. C.; Wilson, I. A.; Lesley, S. A.;

Woods, V. L., Rapid refinement of crystallographic protein construct definition employing
enhanced hydrogen/deuterium exchange MS. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (3),
751-756.

155

57.

Innes, B.; Bailey, M.; Brandl, C. J.; Shilton, B.; Litchfield, D. W., Non-catalytic

participation of the Pin 1 peptidyl-prolyl isomerase domain in target binding. Front. Physiol.
2013, 4, 1-10.

58.

Wales, T. E.; Fadgen, K. E.; Gerhardt, G. C.; Engen, J. R., High-Speed and High-

Resolution UPLC Separation at Zero Degree Celsius. Anal. Chem. 2008, 80, 6815-6820.
59.

Weis, D. D.; Engen, J. R.; Kass, I. J., Semi-automated data processing of hydrogen

exchange mass spectra using HX-Express. J. Am. Soc. Mass Spectrom. 2006, 17 (12), 17001703.
60.

Jager, M.; Dendle, M.; Kelly, J. W., Sequence determinants of thermodynamic

stability in a WW domain-An all-beta-sheet protein. Protein Sci. 2009, 18 (8), 1806-1813.
61.

Mortenson, D. E.; Kreitler, D. F.; Yun, H. G.; Gellman, S. H.; Forest, K. T., Evidence

for small-molecule-mediated loop stabilization in the structure of the isolated Pin1 WW
domain. Acta Crystallogr. Sect. D-Biol. Crystallogr. 2013, 69, 2506-2512.
62.

Zhang, Y.; Daum, S.; Wildemann, D.; Zhou, X. Z.; Verdecia, M. A.; Bowman, M. E.;

C., L.; Hunter, T.; Lu, K. P.; Fischer, G.; Noel, J. P., Structural Basis for High-Affinity
Peptide Inhibition of Human Pin1. ACS Chem. Biol. 2007, 2, 320-328.

156

Chapter 6. Summary and Future Work

6.1. Summary
The work described in this thesis showed how both global and local HDX-MS analysis can
be used for the study of protein structure. Spatially resolved HDX information gives useful
information about the regions of the protein undergoing conformational changes however,
global probing is always a useful first experiment. Global probing is usually fast and it cuts
down on unnecessary experiments. Also, the experimental conditions can be fine-tuned prior
to enzymatic digests. The ultimate goal in this work was to improve the understanding of
protein-ligand binding interactions as it pertains to HDX-MS.
In Chapter 2, native oxy-Hb and aquomet-Hb were exposed to deuterium. It was
found that deuteration pattern in these two proteins were quite different with aquomet-Hb
having a higher deuterium uptake after 6 hours. HDX analysis at the peptide level indicates
that crystallized Hb does not represent the solution-phase structure adequately. Oxy-Hb also
showed an increase in the deuterium uptake near the heme binding site.
In subsequent studies (Chapter 3), the structural dynamics in hemoglobin and
myoglobin were studied. Heme binding to apo-Mb resulted in a decrease in deuterium
incorporated into the backbone of the protein. This result is in agreement with other HDX
binding studies. Binding of oxygen to hemoglobin or myoglobin, however, resulted in an
increase in the uptake of deuterium with hemoglobin exhibiting the larger increase of the two
proteins. It appears that the increase in measured HDX kinetics was not limited to multimeric
proteins like hemoglobin. A thermodynamic model for the different scenarios encountered in
HDX measurements is thus provided in this chapter.

Having established that protein-ligand interactions can lead to both stabilization or
destabilization of the protein receptor, Chapter 3 explored the interaction between an
antibacterial drug target ClpP and ADEP (an antibiotic compound). Binding cause noticeable
changes at the binding site, but allosteric interactions can be triggered as well. This is
particularly important for protein-ligand studies that seek to map the binding site of a drug to
its target. The results also suggest that ligand binding to ClpP induces an opening of the axial
pore as demonstrated in the increased HDX kinetics in this region.
Chapter 5 focused on the structural changes in Pin 1 a peptidyl prolyl isomerase.
CREPEVEIC, a cyclic peptide, is a known inhibitor of Pin 1 however efforts to crystallize
Pin1-CRYPEVEIC complex have proved unsuccessful. The HDX kinetics of Pin 1 in the
WW domain remains unchanged in the presence of ligand. The PPIase domain, however,
shows a dramatic difference before and after ligand binding. Of particular interest is a group
of residues in the loop region known to interact with the phosphate groups of the ligand. This
loop became destabilized after ligand binding due to steric effect.

6.2. Future Work
6.2.1. Application of HDX to Other Proteins
HDX is a powerful tool for probing the structural dynamics of proteins, but this technique
works best only for soluble proteins. The size and type of systems that can be studied using
HDX-MS are endless. The goal is to study larger and more complex systems. The work in
Chapter 4 looks at ClpP with a small binding partner. It will be interesting to investigate
ClpP interaction with AAA+ proteins such as ClpX or ClpA. 1-3 Global and peptide analysis
will help understand how ClpP functions with its natural binding partner. The experiment can
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also be tuned to look at the structural changes in ClpA (ClpX) as a function of binding to
ClpP. Another interesting class of protein to study is integral membrane proteins.
Integral membrane proteins represent a large proportion of the current drug targets which
indicates their role in cellular processes. Membrane proteins are water insoluble and prone to
aggregation. They represent the most difficult proteins to study by HDX-MS. Previous MS
structural studies have utilized detergents as solubilizing agents which allows the acquisition
of global HDX information. 4-5 It will be interesting to explore the development of improved
HDX-MS protocols for membrane proteins

6.2.2. Application of HDX to Intrinsically Disordered Proteins (IDPs)
IDPs represent a special family of proteins lacking a unique tertiary structure at physiological
pH. IDPs are predicted to perform various function and they have been shown to be
associated with human diseases like cancer and neurodegenerative diseases.6

HDX is

routinely used to detect disordered regions in a protein. The ability of HDX to report on the
structure of the polypeptide chain gives it an advantage over other optical methods that rely
of select chromophores. HDX has been successfully applied in the study of the interaction
between ACTR (activator of thyroid and retinoid receptors) and CBP (binding domain of the
CREB binding protein).7 Extending this technique to other IDPs would be very informative.
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